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Abstract (English) 
 
Linear localized scleroderma (LLS) is a rare connective tissue disorder (<2.7/100’000 per year) 
characterized by chronic inflammation and massive accumulation of collagen. This results in 
hardening and thickening of the lesion leading to the affected areas to cave in from atrophy. 
The sharply delimited and linear lesions can affect patients anywhere on the skin and mostly 
on the face in the clinical subtype’s en coup de sabre and Parry-Romberg syndrome. This leads 
to disfigurement and impaired quality of life. The disease affects mostly children and 
treatment options are limited and most often unsatisfactory. 
Very little is understood about the condition in terms of genetic and clinical aetiology. There 
is evidence that LLS might be based on genetic alterations in affected tissues. Blaschko’s lines 
are the patterns of cell migration and proliferation during embryological development. 
Multiple skin conditions have been shown to follow Blaschko’s lines including LLS. Several of 
these diseases are caused by genetic factors such as a de novo somatic mutation producing 
cutaneous mosaicism. Here, we test the hypothesis that LLS is caused by a somatic genetic 
protein-coding mutation. 
The whole exome of blood and affected skin taken from 19 confirmed LLS patients was 
sequenced. Oligonucleotides complementary to the protein-coding DNA regions were used 
for library preparation. Sequence analysis was performed with GATKv3.5. To further validate 
results, 4 patients with similar lesions were chosen for deep sequencing (DP of >300). 
However, somatic analysis of these samples revealed no potentially causative mutation. CGH 
was performed on 3 patients to find large scale chromosomal aberrations too large to be 
detected by WES. Samples were compared with 3000 control karyotypes. Germline analysis 
of samples against 80 controls also did not reveal any driving factor. HLA signals were 
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determined between the 19 cases and 60 controls, no allotype was significantly associated 
with LLS. A limitation of this project is the lack of intronic, intergenic and epigenetic data. 
Taken together, the in-depth analysis performed in this work allowed us to disprove the 
hypothesis that a somatic exonic event causes LLS.  
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Abstract (German) 
 
Linear lokalisierte (zirkumskripte) Sklerodermie (engl.: linear localized scleroderma = LLS) ist 
eine seltene Bindegewebserkrankung (Neuerkrankungen <2.7 pro 100.000 Personer im Jahr), 
welche sich in chronischer Entzündung und massiver Ablagerung von Kollagen in der Haut 
manifestiert. Durch diese Anreicherungen von Kollagen kommt es zu verhärteten 
Hautläsionen, welche sich durch Atrophie wieder abflachen. Die scharf abgegrenzten und 
linearen Läsionen können überall auf der Haut auftreten, jedoch speziell bei den klinischen 
Subtypen en coup de sabre und Parry-Romberg Syndrom finden sich diese im Bereich des 
Gesichtes. Dies führt regelmässig zur Entstellung und beeinträchtigter Lebensqualität. Die 
Krankheit tritt am häufigsten bei Kindern auf und die Behandlungsmöglichkeiten sind limitiert 
und unbefriedigend. 
Es ist nur wenig bekannt über die genetischen und klinischen Ursachen dieser seltenen 
Krankheit. Es gibt aber Hinweise, dass lineare lokalisierte Sklerodermie auf genetischen 
Mutationen in den betroffenen Bereichen basiert. Die sogenannten Blaschko-Linien 
beschreiben embryonale Wachstumslinien der Haut, entlang dieser während der 
Embryonalentwicklung Zellproliferation und Migration stattfindet. Multiple 
Hautveränderungen sind den Blaschko-Linien zugeordnet, einschliesslich linear lokalisierte 
Sklerodermie. Einiger dieser Erkrankungen werden durch genetische Faktoren ausgelöst, wie 
zum Beispiel de novo somatische Mutationen, welche ein kutanes Mosaik erzeugen. In dieser 
Arbeit wurde die Hypothese getestet, ob linear lokalisierte Sklerodermie durch somatische 
Mutationen in protein-kodierenden Genombereichen ausgelöst wird.  
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Aus Blut und betroffener Haut von 19 Patienten mit gesicherter linear lokalisierter 
Sklerodermie wurde DNA isoliert und alle darauf befindlichen protein-kodierenden 
Abschnitte (Exon) sequenziert (engl. WES=whole exome sequencing). Mit Hilfe von für 
protein-codierende Sequenzen komplementären Oligonukleotiden wurde aus der Patienten-
DNA eine sogenannte «library» hergestellt. Diese besteht aus amplifizierten DNA 
Fragmenten, welche später mit bekannten DNA Fragmenten hybridisiert und sequenziert 
werden. Die Resultate der Sequenzierung wurden mit Hilfe der GATKv3.5 Software analysiert. 
Um die Resultate weiter zu validieren, wurde bei 4 phänotypisch sehr ähnlichen Patienten ein 
noch gründlicheres «deep sequencing» durchgeführt. Hierbei werden mindestens 300 
amplifizierte DNA Fragmente des gleichen Typs sequenziert. Mit Hilfe der CGH Technologie 
(comperative genomic hybridization) können grosse chromosomale Veränderungen 
analysiert werden, welche durch die WES Methode nicht detektiert werden. Die DNA Proben 
von 3 Patienten wurden mit Hilfe von CGH analysiert und zu 3000 Karyotypen aus 
Kontrollgruppen verglichen. Die Keimbahnmutationen der Proben wurden auch mit 80 
Kontrollproben verglichen. Schliesslich wurden auch die HLA Klasse I Allotypen bestimmt und 
die 19 Patienten mit der Normalpopulation verglichen. In allen diesen Untersuchungen zeigte 
sich keine krankheitsverursachende Mutation, chromosomale Aberration oder HLA-Signal . 
Eine Limitation dieses Projektes ist das Fehlen von intronischen, intergenetischen und 
epigenetischen Daten.   
Zusammengefasst konnte mit den in dieser Arbeit durchgeführten intensiven und 
detaillierten genetischen Analysen die Hypothese widerlegt werden, dass somatische 
Mutationen für die Entstehung der linear lokalisierten Sklerodermie eine Rolle spielen.  
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Introduction 
 
Linear Localized Scleroderma 
 
1. Background  
 
Linear localized scleroderma (LLS) is a rare disorder of the connective tissue. It is characterized 
by chronic inflammation and massive deposition of collagen and an increase in extracellular 
matrix production. This leads to hardening and thickening of the area, which eventually caves 
in from atrophy leaving the patients with an indurated linear lesion(s) (Weibel and Harper 
2008, Fett and Werth 2011, Majewski, Schwartzentruber et al. 2011). The disease is not fatal 
but can lead to cosmetic disfigurement, especially if the lesion is located on the face. LLS is 
generally limited to cutaneous and subcutaneous tissues and is self-limiting in most cases  
(Weibel and Harper 2008). In some, more severe, cases there may be involvement of the 
muscle and bone underlying the lesion. The extracutaneous involvement can lead to side 
effects such as arthritis, epilepsy, arthralgia and uveitis (Christen-Zaech, Hakim et al. 2008, 
Fett and Werth 2011). The disease is not always self-limiting and can progress over the years 
causing irreversible structural deformities such as joint contractures and mental disabilities 
like epilepsy (Weibel and Harper 2008). 
LLS is a subtype of localized scleroderma (LS). LS is more commonly known clinically as 
morphea. Morphea is the preferred term in the clinical setting to avoid patient confusion with 
systemic sclerosis (SSc) which could cause unnecessary confusion and concern. LLS is the 
subtype of morphea where plaques or lesions are in a linear form. The linear presentation of 
morphea is the most common of the five subtypes to be found in children. Pediatric morphea 
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is estimated to be of the linear subtype in 40-70% of cases (Kreuter, Krieg et al. 2009, Weibel, 
Laguda et al. 2011, Marsol 2013).  
The average age of onset of LLS is roughly 6 years of age (Zulian, Athreya et al. 2005). However 
congenital presentation has been described in both morphea and LLS (Zulian, Vallongo et al. 
2006). The estimated incidence of morphea is 1-2.7 per 100,000 individuals. There is as of yet 
no specific data available for the incidence of LLS. This could be due to the difficulty in 
diagnosis of morphea and the difficulty in differentiation of LLS from other subtypes of 
morphea. Women are estimated to be affected by morphea 2.1-6 times more often than men 
and specifically LLS has been found in two studies to be 2.2 times more likely in women than 
men (Orozco‐Covarrubias, Guzmán‐Meza et al. 2002, Zulian, Athreya et al. 2005, Tollefson 
and Witman 2007).  
Previous studies have been ethnically diverse and despite the presence of morphea in all 
races, it has been shown to affect predominantly Caucasians (72.7-82%) (Amaral, Peres et al. 
2013). In a study of 44 patients with LLS by Christen-Zaech et al. 2008, 37 were Caucasian, 5 
were Hispanic, 1 Asian and 1 African American. The same ethnic distributions were also found 
in other subtypes of morphea (Christen-Zaech, Hakim et al. 2008). As of yet there is no 
explanation for the unequal distribution in ethnicities.  
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2. Classification 
 
The first system of classification of the subtypes of morphea was described in Peterson et al. 
1995. This study concluded there are 5 subtypes of morphea; Plaque (keloidal sclerosis, 
atrophoderma of Pasini and Pierini guttate, lichen sclerosis), Generalized (morphea lesions on 
two or more areas), Bullous, Deep (eosinophilic fasciitis, Pansclerotic morphea, morphea 
profunda, subcutaneous morphea) and Linear (ECDS, PRS, linear lesion of extremities)  
(Peterson, Nelson et al. 1995). This classification system over time has not been widely 
accepted, as many of the disorders such as eosinophilic fasciitis are separated as a distinct 
disease. In addition, this classification system does not take into account the 15% of cases 
where patients have more than one subtype of morphea (Fett and Werth 2011). 67% of 
morphea in children is reported to be LLS. The second most common subtype is plaque type 
morphea (26%), followed by generalized morphea (7%) and deep morphea (2%). 
Another system of classification was described by Laxer and Zulian in 2006 and has now 
become the more widely accepted version. This new system of classification was necessary 
as some diseases in the old classification system were not actually morphea and did not 
account for the occurrence of more than one subtype of morphea in a patient. This 
classification system is the commonly used system in clinical analysis of morphea patients. 
This classification also describes 5 subtypes (Table 1) (Laxer and Zulian 2006, Fett and Werth 
2011). These subtypes are circumscribed, generalized, pansclerotic, linear and mixed (Figure 
1).  
The circumscribed subtype is the most common type of morphea which has two subtypes, 
superficial and deep. The superficial subtype is limited to the cutaneous regions and the deep 
subtype can extend into muscle. Generalized morphea has widespread involvement and is 
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most often limited to the dermis. The mixed subtype is described in roughly 15% of morphea 
patients. This is when a patient has two morphea subtypes, most commonly one of them will 
be LLS. The most debilitating morphea subtype is pansclerotic. Its effects can extend from the 
dermis into the bone and result in chronic wounds. Morphea is generally not fatal however, 
fatal pansclerotic morphea has been described in a study of an 11-year-old patient with a 
history of pansclerotic morphea on her trunk, which over 2 years expanded to affect her 
entire body. It rapidly became ulcerative and eventually resulted in death (Hardy, Audouin-
Pajot et al. 2016). Pansclerotic morphea has also been linked to squamous cell carcinoma 
(SCC) with 6.7% of pansclerotic morphea patients estimated to develop SCC (Fett and Werth 
2011).  
 
Subtype Description  
Circumscribed 
/Plaque morphea 
Ovular areas of induration. Has two subtypes, superficial and deep. 
Superficial type is limited to the dermis and epidermis. Deep type 
extends into subcutaneous level and underlying bone. 
Generalized 
morphea 
This describes widespread lesions, ≥4 plaques on ≥2 sites of the body. 
Linear localized 
scleroderma 
Linear lesions on limbs and trunk. Also includes facial subtypes ECDS and 
PRS. Involves dermis, subcutaneous and rarely muscle and bone. 
Pansclerotic 
morphea 
Circumferential involvement of skin, subcutaneous, muscle and bone.  
Mixed morphea Involves more than one subtype to be present. Most commonly, the 
linear subtype is found alongside another subtype. It occurs in up to 15% 
of patients. 
Table 1. Classification of morphea into 5 subtypes as proposed by Laxer and Zulian in 2006.  
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Figure 1. Subtypes of morphea other than LLS.  
A) Generalized morphea (Neustadter, Samarin et al. 2009),  
B) Circumscribed morphea superficial (www.cursoenarm.net) and  
C) Pansclerotic morphea (Ana-Maria, Aura-Nicoleta et al. 2008) 
 
 
 
 
A B 
C 
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3. Pathogenesis and triggers  
 
Pathogenesis has been shown to be largely similar in LLS, morphea and SSc in terms of skin 
involvement. Early skin biopsies in all three diseases show damaged endothelial cells 
sometimes years before fibrosis. Vessels in the area lose their elasticity due to the outer layers 
of the vessels becoming rigid and fibrotic. A high concentration of mononuclear lymphocytic 
cellular infiltrates in dermal and subcutaneous regions have been described in morphea skin 
biopsies. This indicates inflammation as a precursor to fibrosis (Fleischmajer, Perlish et al. 
1977). It has also been shown that fibroblasts of scleroderma skin produce more collagen than 
those of normal skin (Johnson and Ziff 1976, Rodnan, Lipinski et al. 1979).  
 
 
 
Figure 2. 
Hyperpigmentation from 
inflammation in early 
stage ECDS 
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The “classic evolution” of morphea begins with an erythematous patch that slowly becomes 
yellowish and white and features blue-violet erythema at the edge. Subsequently, post-
inflammatory hyperpigmentation of underlying tissues ensues (Figure 2). This is generally 
considered the early-stage of the disease (Kreuter, Krieg et al. 2009). The progression of LLS 
can vary from patient to patient. Often the early inflammatory stage can be intensely 
erythematous, leading to a misdiagnosis of common port-wine stain (Weibel, Laguda et al. 
2011).  
In contrast, the inflammatory stage at the skin surface may be delayed with atrophy of 
underlying tissue occurring rapidly. Clinical features that can help in distinguishing LLS from 
other diseases in early stages, is the distribution along Blaschko’s lines, loss of hair on the 
scalp or eyebrow, skin fibrosis, atrophy of the skin and age of the patients. When lesions are 
found on the face it is also important to search for facial asymmetry from atrophy of 
underlying tissues (Figure 3) (Weibel, Laguda et al. 2011).  
The late-stage of the disease develops when the affected area begins to harden and thicken 
(Kreuter, Krieg et al. 2009). This is caused by a massive increase of collagen in the area. This 
collagen is closely packed becoming dense and leads to fibrosis. The fibrotic regions become 
hard and discoloured and eventually atrophy will occur (Torok and Arkachaisri 2012). Atrophy 
in the area can lead to impairment of growth and limb function, especially in growing children. 
It has been shown that the skin that is affected in all subtypes of morphea can soften over 
time when the area has been inactive for a long time. However the other types of damage 
such as atrophy and dyspigmentation are permanent. In LLS, the contractures caused by 
muscle damage are permanent (Szramka-Pawlak, Dańczak-Pazdrowska et al. 2014). 
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What trigger causes this damage remains unknown as yet. Many events and environmental 
stimuli have been implicated. Mechanical damage appears to be the most cited culprit: A 
traumatic event to the area has been described as a precursor to disease manifestation in 
many studies (Yamanaka and Gibbs 1999). In a large-scale study by Zulian and Athreya et al. 
2005 based on the clinical evaluation of 750 young patients with morphea, 489 patients were 
determined to have LLS. 100 patients were studied to unearth the preceding factors that 
possibly lead to onset of morphea. 69 of these patients had LLS. 51 patients reported the 
onset was due to mechanical factors (40 = trauma, 8 = Insect bites and 3 = vaccination). Of 
Figure 3. Asymmetry from 
LLS lesion on the left 
paranasal area. Figure 
from our own clinical 
cohort. 
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the patients who reported trauma, 12 patients reported that it was due to infection, 3 
reported it was a response to drug therapy and 3 reported it was due to previous 
psychological distress (Zulian, Athreya et al. 2005).  Sunburn and lichen striatus that preceded 
the development of morphea have also been reported (Christen-Zaech, Hakim et al. 2008). 
Childhood head injury was implicated by 27% of respondents in an internet survey of 205 
patients (Stone 2003). 
Infections with Borrelia burgdorferi, commonly known as Lyme disease, have also been 
implicated in the disease progression. This assertion is an area of contention. One study 
concluded that infections with Lyme disease have late-stage skin involvement in the form of 
fibrotic nodules, which eventually progress to other skin diseases like morphea (Malane, 
Grant-Kels et al. 1991). This association between morphea and Lyme’s disease has been 
widely questioned with some papers finding a significant relationship between B. burgdorferi 
antinuclear antibodies in the blood of morphea patients (Prinz, Kutasi et al. 2009), whilst 
others did not confirm any associations (Hoesly, Mertz et al. 1987, Kreuter, Krieg et al. 2009). 
B. burgdorferi survives in certain environments, so its geographical distribution has been well 
mapped out. The same can also be said for clinical incidence of Lyme disease. As of yet no 
work has been done to investigate the relationship between morphea incidence vs Lyme 
disease incidence from a geographic standpoint.  
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4. Complications and co-diagnosis of LLS and morphea 
 
For the patient, aside from the skin involvement, LLS is usually asymptomatic with sometimes 
itchiness and mild pain reported. The largest problem for children is the gradual growth of 
healthy tissue that is not matched by the atrophied and hardened lesions. This effect can even 
lead to impaired bone growth in patients with lesions on arms and legs. Joint movement can 
also be restricted. ECDS and PRS can also result in seizures as the lesion extends towards the 
brain (Fett 2013).  
In a partially retrospective study of paediatric morphea in 136 patients, non-cutaneous 
manifestations were found to be more common in the 44 LLS patients who had lesions on the 
body rather than the face.  Several patients had musculoskeletal issues due to LLS. Arthralgia 
was diagnosed in 13 patients. Muscular cramps and scoliosis was diagnosed in four and two 
patients respectively. 10 patients with lesions on the face had CNS involvement which was 
predominantly migraines, seizures and stroke. Of the 44 patients with no facial lesions, only 
three had CNS involvement. These patients had seizures, headaches and dyspnea. Another 
three patients also had gastrointestinal problems such as reflux, dysphagia and general 
abdominal pain (Christen-Zaech, Hakim et al. 2008).  
In this same study of the patients with ECDS (n=23) and PRS (n=3), none of the patients were 
diagnosed with musculoskeletal side effects and gastrointestinal problems. Of the ECDS 
patients, 10 were affected by headaches and seizures with one patient suffering a stroke. No 
CNS involvement was found in the PRS patients (Christen-Zaech, Hakim et al. 2008). 
This study also investigated co-morbidity with other autoimmune diseases (AI) in LLS patients. 
The AI history of extended and immediate families were also included. In the patients with 
non-facial LLS, two patients were found to have juvenile rheumatoid arthritis. Vitiligo, 
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psoriasis, alopecia areata and Crohn’s disease were also described in individual patients. In 
the family members, five had rheumatoid arthritis, two had systemic lupus, two had 
thyroiditis, two had systemic scleroderma and one had celiac disease. Family members of the 
three PRS had no history of AI. One PRS patient suffered from alopecia areata. One ECDS 
patient had juvenile dermatomyositis. In family members of ECDS patients, only three family 
members had AI such as autoimmune thyroiditis, psoriasis or type I diabetes.  
Some studies have reported fatigue, myalgia, malaise and arthralgia appearing with morphea 
(Fett and Werth 2011). Rheumatologic, ophthalmologic and neurologic symptoms have also 
been described in many LLS patients (Amaral, Marques Neto et al. 2012). 
LLS is also the most likely form of morphea to present with another subtype of morphea 
resulting in a diagnosis of the mixed subtype (Fett and Werth 2011). In a study of 750 patients 
with morphea 15% of children had the mixed subtype. LLS was found alongside circumscribed, 
superficial and deep forms. LLS lesions appeared before or at the same time as the other 
plaques in 64% of patients. The mixed form is not easily recognizable at the clinical level and 
confusion can result. The treatment for the mixed subtype is difficult as treatment options for 
different subtypes vary (Zulian, Athreya et al. 2005).   
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5. Diagnosis of LLS 
 
Differential diagnosis of LLS from other subtypes is difficult in some patients. Some confusion 
can occur in patients with mixed diagnosis, however there are 4 factors that are helpful in 
separating LLS from the other subtypes: 
1) Depth of the lesions: LLS has extracutaneous involvement, which is not common in 
generalized and superficial circumscribed morphea. 
2) The linear nature of the lesions with sharply delimited borders are the most significant 
indicators of LLS.  
3) The patient’s age is also very helpful in diagnosis. LLS is the most common morphea 
subtype in children and its onset is roughly 6 years of age.  
4) Adherence to BL is also an indicator of LLS.  
The initial diagnosis of LLS or morphea can be difficult. There are the classical symptoms and 
onset as described previously but the agreed “classical evolution” (discussed in section 1.3) is 
most often not the way both diseases progress. There is significant variation in the clinical 
presentation, hence the rate of misdiagnosis is non-negligible. Factors involved in 
pathogenesis in morphea and LLS are important for diagnosis. Early stage yellowish-white 
erythematous patches with violet edges are helpful in diagnosis. After the inflammatory 
stage, hyper-/hypopigmented lesions are also indicative of morphea and LLS. More helpful in 
diagnosis is the hardening, loss of elasticity and thickening of the skin. 
Here, some tools a techniques used in diagnosis of morphea and LLS are described.  
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5.1 Histology 
 
Dermatopathology reveals the microscopic pattern of inflammation and structural pathology, 
which is crucial for the diagnosis of LLS. All subtypes of morphea are divided into two phases, 
early and late. In the early phase, there are often dense periadnexal and perivascular 
inflammatory in the dermis. Cellular infiltrates are also found, mainly lymphocytes, plasma 
cells and histiocytes. More rarely, eosinophilic granulocytes are present. Edema is sometimes 
found in the upper dermis. Thickened collagen fibres are found in the upper dermis. Late stage 
morphea is recognizable by the presence of sclerosis and atrophy of sweat glands. Also, the 
walls of blood vessels are thicker and there are signs of inflammation (Figure 4) (Kreuter, Krieg 
et al. 2009).  
 
 
 
 
Figure 4. Histology of early morphea 
shows lymphocyte infiltrate and 
enlarged endothelial cells and collagen 
bundles. Hematoxylin-eosin stain; 
original magnification, x103 (Fett and 
Werth 2011). 
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5.2 Laboratory techniques 
 
A myriad of laboratory tests can be utilized to aid the clinician in their diagnosis. Some 
diseases can be identified promptly as these test results can clearly implicate a certain 
disease. Therefore it would be attractive to find a serologic marker, cellular infiltrate or 
autoantibody that directly implicates morphea as the correct diagnosis. Furthermore, 
identifying a factor to differentiate LLS from other subtypes of morphea would be very 
interesting and potentially useful as well.  
Laboratory tests performed on 474 LLS patients at the time of diagnosis showed some 
abnormalities, and discordance between other subtypes of morphea. The patients were 
tested for their eosinophil cell blood count, which was reported to be abnormal in 12% of LLS 
patients (57/474), this rate was higher in circumscribed superficial and generalized morphea 
(18.4% and 13.7% respectively) and much higher in the circumscribed deep form (62.5%) 
(Zulian, Athreya et al. 2005).  
Erythrocyte sedimentation rate (ESR) was increased in 22.2% of patients (102/460) similar to 
that of deep morphea with an abnormal level in 25% of patients. In 249 tested patients with 
LLS, IgA, IgG and IgM was increased in 12.4%, 20.9% and 16.1% of patients respectively. These 
results are similar to plaque morphea (13.5%, 14.9% and 8.1%) and generalized morphea 
(11.8%, 11.8% and 9.5%). IgA and IgM in deep morphea are similar to other types of morphea 
(18.8% and 6.2%) however, IgG was much higher at 56%. Antinuclear antibodies (ANA) were 
tested in 446 LLS patients and found positive in 47.3% of patients. This is similar to other 
morphea subtypes ranging from 31.3%-43% positive ANA serologies (Zulian, Athreya et al. 
2005).  
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Antihistone antibodies and ssDNA are usually positive in LLS as well (Sartori-Valinotti, 
Tollefson et al. 2013). These factors can be helpful in diagnosis but are largely limited as no 
statistical work has found a true correlation. 
 
5.3 Measurement tools that are considered in assessment 
 
Thermography 
 
Thermography has been suggested as a method to measure disease activity. This uses infrared 
imagery to assess the surface temperature of the skin. It involves acclimatizing in a 
temperature-controlled room after which the images are taken using an infrared camera. The 
surface temperatures are contralaterally compared, focusing on affected and non-affected 
regions. It has been found that there is a significant but small increase of 0.29°C in lesions that 
are active.  
This small change in temperature could be explained by inflammation and microcirculatory 
changes in the lesions. This change in temperature is interesting. The usefulness of this 
technique is limited and only relevant in active lesions and there have been false positives 
found in inactive lesions (Birdi, Shore et al. 1992, Garcia‐Romero, Randhawa et al. 2017). This 
has been theorized to be due to the lack of subcutaneous tissue from the disease increasing 
thermal conductivity of the epidermis. Given that it is not possible to distinguish active and 
inactive lesions, using thermographic measurements may not be useful in diagnosis (Garcia‐
Romero, Randhawa et al. 2017).  
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Durometer 
 
This is a tool, which measures and evaluates skin hardness of the affected skin relative to the 
contralateral unaffected area. Due to collagen build-up in the area there is a notable increase 
in hardness in affected areas. This tool depends on factors such as oedema, sex and age of 
patients, and location (Fett and Werth 2011). It is easy to use and has been shown to have 
low variability between patients. It unfortunately has low correlation with skin scores and is 
therefore not commonly used (Fett and Werth 2011). 
 
Cutometer 
 
A cutometer is a device to measure the elasticity and relaxation of skin. A vacuum pump is 
applied to an 8 mm diameter area of skin. Elasticity is assessed by measuring skin disruption 
followed by time for skin to return to baseline (relax) (Fett and Werth 2011). Elasticity of the 
skin is affected by the fibrosis and atrophy of LLS affected skin. This technique has been shown 
to be helpful in other skin diseases but has not been validated in any studies on LLS (Dobrev 
2005, Kreuter, Krieg et al. 2016).  
 
Ultrasound 
 
Use of a 20 MHz ultrasound has been shown to have use in diagnosis of LLS. It can be used to 
visualize the top centimetres of the skin. Echogenicity is altered especially in the later stages 
of morphea. As edema and inflammation decrease echogenicity increase. Furthermore 
sclerosis increases as the disease progresses and this results in a corresponding increase in 
echogenicity. Use of a 20 MHz ultrasound shows a thickened and hypoechoic dermis that is 
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not present in normal skin. This method has been shown to be reproducible, it has recently 
been validated (Bendeck and Jacobe 2007, Kreuter, Krieg et al. 2009).  
 
 
6. Data collection in LS and LLS 
 
Decisions on treatment and disease management options can be very difficult for a 
practitioner especially if there is no standardized criteria for assessment and treatment. There 
are several reasons why no double-blind studies have been performed on any of the available 
morphea treatments. The main obstacle is that it is a rare disease, thus gathering sufficient 
volumes of data and information is difficult. Furthermore, in the case of rare diseases and 
especially non-fatal ones, pressure to gather data of good and comparable quality is not 
omnipresent.  
The most widely used score for morphea and the score used in this study is the Localized 
Scleroderma Severity Index (LoSSI). This score describes the disease activity by 4 assessment 
criteria. Each criteria is scored in a scale of 0 to 3 based on least to most severity with the 
exception of the 4th criteria.  
1) The surface area score. 14 cutaneous sites are assessed throughout the body. Each 
area is scored on a scale of 0 to 3 with how much of the surface area of the site is 
affected. A score of 0 at one site means there is no lesion. A score of 3 means over 2/3 
of the site is covered by a lesion.   
2) The erythema score. This scores the inflammation by severity focusing on the edges 
of the lesion and scoring from 0: normal to 3: dark red or marked erythema. 
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3) Skin thickness. This is assessed by palpation of the skin which is scored on a scale of 0 
to 3. 0 is normal skin and 3 is marked increase in thickness and limited mobility to the 
skin. 
4) Development of new lesions. If a new lesion appears within one month of the last 
consultation a score of 3 is given.  
However, there are limitations of this score the most important of which is it doesn’t take 
damage caused by the disease into consideration. There is a score describing damage called 
the Localized Scleroderma Damaging Index (LoSDI). This score describes the level of damage 
to the area. Damage is defined as irreversible or persistent change (Arkachaisri, Vilaiyuk et al. 
2009). The three criteria are dermal atrophy (DAT), subcutaneous atrophy (SAT) and hyper-
/hypopigmentation all of which are scored on a scale 0-3 (0 = normal skin, 3 = severe 
phenotype). 
It can be concluded from literary research that patients with all subtypes of morphea have 
limited treatment options, the success of which vary drastically. The biggest issue facing 
doctors is the lack of standardized diagnosis and treatment protocols for patients. The 
Childhood Arthritis and Research Alliance (CARRA) are attempting to establish such a 
protocol, however it is proving slow and difficult. The best solution for this is to create 
standard and verified useful tools for collection of patient data.  
Due to the phenotypic variability and subsequent difficulties / delays in diagnosis, thoroughly 
collected data cannot be compared inter-patient. Creation of a “gold standard analysis” for 
practitioners should alleviate uncertainty, workload and inaccuracy. A new skin scoring 
technique has been described called Localized Scleroderma Assessment Tool (LoSCAT). This 
tool combined the LoSSI and LoSDI. This method has shown some promise in data collection 
29 
 
hopefully leading to standardization and laying the groundwork for extensive testing of 
treatments (Arkachaisri, Vilaiyuk et al. 2009). LoSCAT attempts standardize the assessment of 
morphea patients between doctors in treatment centres worldwide. This will facilitate 
complete characterization of the rare disease and strengthen meta-analysis. This could lead 
to double-blind testing of drugs on patients and hopefully a more personalized and thus 
effective treatment approach in patients (Marsol 2013).  
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7. Subtypes of facial LLS 
 
There are two subtypes of LLS that are found on the face and head, en coup de sabre (ECDS) 
and Parry-Romberg syndrome (PRS). Both disorders are often mistaken for each other at the 
clinical level due to the facial asymmetry that results from both and neurological issues that 
can also accompany both diseases (Orozco‐Covarrubias, Guzmán‐Meza et al. 2002). No 
diagnostic markers to completely differentiate the two diseases exist. However, cutaneous 
markers, histopathology and clinical examinations are very useful in the differential diagnosis. 
In spite of this, there are still many cases where differentiating the two has eluded even the 
most experienced histopathologists and clinicians. It is for this reason that it remains difficult 
to completely describe and understand the relationship of these two LLS facial subtypes.  
 
7.1 En Coup de Sabre (ECDS) 
 
ECDS is one of the subtypes of LLS located on the head. It is so called due to its likeness to a 
strike from a sword. EDCS lesions are hyperpigmented, sclerotic, shiny and hairless. Alopecia 
of the area that arises if the lesion is in or extends to the scalp. This is often the reason the 
patient first seeks medical attention (Figure 5) (Orozco‐Covarrubias, Guzmán‐Meza et al. 
2002). Lesions are most often located on the frontoparietal scalp, median and paramedian 
forehead and sometimes extend into the scalp, maxillary area and side of the nose (Figure 6) 
(Tollefson and Witman 2007). This pattern has also been noted to follow the upper trigeminal 
nerve (Gambichler, Kreuter et al. 2001). In most cases, ECDS will not extend past the midline 
of the face but it has in some cases extended down to the upper lip or chin (Figure 7). It 
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appears unilaterally, however a few cases of bilateral involvement has been noted (Rai, Handa 
et al. 2000, Gambichler, Kreuter et al. 2001).   
ECDS appears in most patients before 10 years of age (Orozco‐Covarrubias, Guzmán‐Meza et 
al. 2002). Congenital presentation of ECDS has been described, however, it is very rare (Zulian, 
Vallongo et al. 2006).  
 
 
 
Figure 5. Alopecia in ECDS, 
extending from the forehead into 
the scalp. Figure from our clinical 
cohort. 
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Figure 6. ECDS A) lesion on the 
right forehead B) Second lesion of 
ECDS on the right temporal of the 
same patient. Some alopecia 
present. Lesion from skin biopsy                 
C) Lesion on right temporal region 
of a patient extending to the eye 
of a second patient. All figures 
from our clinical cohort.  
A B 
C 
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Some studies have shown severe headaches can act as a harbinger of the disease (Polcari, 
Moon et al. 2014). In 4 patients it was observed that severe headaches started 6 months to 3 
years prior to cutaneous onset. In 3 of the 4 cases the headaches appeared localized to the 
area where the cutaneous manifestation developed. These four female patients had severe 
photophobia, dizziness and nausea during their headache spells. The frequency and duration 
of the headaches appear to have no relationship. In one patient, they were as frequent as 45-
minute spells 5 times per day and once a month in another patient. The four patients had 
MRIs but intracranial irregularities in the form of signal intensity at many loci, ipsilateral the 
cutaneous findings, were found in only one patient. This patient had the most severe 
phenotype having suffered from unilateral transient weakness which lead to “stroke-like” 
symptoms, vomiting, migraines and photophobia up to 3 years before the first lesion 
manifested (Polcari, Moon et al. 2014).  
Figure 7. ECDS affecting 
the chin. Figure from our 
clinical cohort. 
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7.2 Parry-Romberg Syndrome (PRS) 
  
PRS is also known in the literature as Progressive Facial Hemiatrophy and more rarely 
Idiopathic Hemifacial Atrophy (Kreuter, Krieg et al. 2016). It is a unilateral, slow progressing 
and self-limiting degeneration of tissues beneath the skin of the face leading to hemifacial 
collapse of varying severities (Blaszczyk, Królicki et al. 2003). It affects subcutaneous tissues 
and there appears to be no cutaneous involvement such as hyperpigmentation or tissue 
hardening as found in ECDS (Orozco‐Covarrubias, Guzmán‐Meza et al. 2002).  
Atrophy affects the underlying muscles and bones which results in one side of the face to cave 
in (Figure 8). It usually takes between 2-10 years for the disease to stop progressing. Some 
studies have described dormant PRS lesions to be triggered to accelerate. In the majority of 
these cases, the apparent trigger was pregnancy and childbirth (68%) with other triggers 
reported to be surgery and stress (Tolkachjov, Patel et al. 2015). Some women have reported 
the PRS lesion to worsen during pregnancy (Stone 2003). There is also reported to be 
involvement with the gums, trigeminal nerve, tongue and palate (Jun, Kim et al. 2011)   
PRS onset is generally before 20 years however, it was estimated in a study of 54 patients that 
the average age of onset is 13.6 years with a range of 0.3 to 75 years (Tolkachjov, Patel et al. 
2015). 66-80% of patients with PRS are female and age of onset is generally before 20 with 
the median age being 10 years old (Stone 2003, Tolkachjov, Patel et al. 2015). 
Neurologic abnormalities, mainly epilepsy has been reported in 10% of PRS patients with 
some reporting seizures. Migraine and facial pain have also been reported. (Blaszczyk, Królicki 
et al. 2003, Stone 2003). PRS was originally described by Romberg as a trophoneurosis i.e. the 
malfunction of trophic nerves (Henoch and Romberg 1846). This theory was later tested by 
disruption of the superior cervical sympathetic ganglion on one side through surgery in animal 
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models (cats, dogs and rabbits) when they were 30 days old. Monthly examinations were 
performed in the following year. The investigators found the development of PRS-like 
symptoms in the animals namely alopecia, ulceration, ocular atrophy and hemifacial atrophy. 
This suggests a relationship between malfunction of the sympathetic nervous system (SNS) 
and PRS (Resende, Dal Pai et al. 1991, Blaszczyk, Królicki et al. 2003). This is interesting when 
you consider many neurologic side effects have also been found in the CNS.  
Like ECDS, the distribution of the PRS atrophy is often observed along the three division lines 
of the trigeminal nerve, which is part of the CNS. The three divisions or branches are the 
ophthalmic nerve, maxillary nerve and mandibular nerve. The divisions and secondary 
branches span the majority of the face. The 3 divisions are joined and surrounded by SNS 
fibres (Go, Kim et al. 2001). Alternatively, the origin of PRS has been suggested to be linked 
to neurocranial malformations and slow viruses (Orozco‐Covarrubias, Guzmán‐Meza et al. 
2002). In addition, vascular damage can be seen in PRS patients, possibly due to inflammation 
of vessels (Tolkachjov, Patel et al. 2015).  
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Figure 8. A) PRS on the right forehead focused on the paramedian region,  
B) PRS affecting the cheek and lip of the same patient resulting in severe atrophy and 
asymmetry (El-Kehdy, Abbas et al. 2012). 
PRS does not have cutaneous sclerotic involvement, therefore treatment options are better 
than in ECDS. Once the patient reaches maturity, reconstructive surgery can be sought, 
whereas in ECDS the patient requires active drug therapy (Orozco‐Covarrubias, Guzmán‐Meza 
et al. 2002).  
In a small, retrospective study by Sommer et al. 2006 it was suggested that there could be 
two subtypes of PRS. Type 1 affects the subcutaneous tissues, primarily the cheek. Type 2 first 
affects the skin and will move on to the deeper tissues as it progresses. The second variant 
overlaps with ECDS. This accounts for the level of overlap and diagnostic confusion.  
In the Sommer et al. 2006 study of 12 patients with PRS type 1 patients (n=5) all but one had 
tongue, lip, salivary gland and gingiva involvement, often in combination. No patients had 
involvement of the trunk or a co-diagnosis of ECDS. Neuroimaging of these patients was all 
normal however 2 patients had neurological symptoms (linguistic and motor delay and 
psychosis).  
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In type 2 PRS patients (n=7) two patients had tongue involvement, one had palsy (nerves III, 
IV, VI, VII) and one patient had a fixed pupil. ECDS was also diagnosed in 5 of these patients. 
One patient had deep morphea, one had LLS and one had plaque morphea. 2 of the 7 patients 
did not have neurologic symptoms. The other patients suffered from a range of neurologic 
symptoms from seizure (Jacksonian, Grand mal) to migraine and one had depression. 
Neuroimaging was not available for two patients and was found to be normal in three 
patients. One patient with no neurologic symptoms had normal neuroimaging whereas the 
other normal patient had no neuroimaging (Table 2) (Sommer, Gambichler et al. 2006). 
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Patient Type Onset 
(years) 
Side Morphea co-
diagnosis 
Intraoral and 
opthamological 
involvement 
Neuologic 
symptoms 
Neuroimaging EEG 
1 1 3 R - Tongue and lips Jacksonian 
seizures and 
migraine 
Frontoparietal subcortical 
hyperintense lesion in FLAIR 
and T1 
Overlaying beta activity 
2 1 3 R Deep 
morphea 
Tongue Normal Normal Parietal sharp wave 
focus 
3 1 7 L ECDS - Grand mal and 
migraine 
Normal Normal 
4 1 6 Bilateral LLS and ECDS Palsy of nerves 
III,IV, VI, VII 
Grand mal, 
palsy of nerves 
Frontoparietal subcortical 
hyperintense lesion in FLAIR 
and T2 
Intermittent bilateral 
frontotemporal theta-
delta-activity 
5 1 27 R ECDS - Depression - - 
6 1 4 L Plaque 
morphea and 
ECDS 
Fixed pupil Grand mal Ventricular dialation, 
subcortical calcification 
Normal 
7 1 10 L ECDS - Normal - - 
8 2 3 R - Salivary glands, 
tongue and lip 
Normal Normal Parietal sharp wave 
focus 
9 2 2 R - Gingiva and 
tongue 
Linguistic and 
motor delay 
Normal Temporal sharp wave 
focus, generalized delta-
rhythm on sleep EEG 
10 2 9 L - Upper lip and 
tongue 
Psychosis Normal Normal 
11 2 16 L - 
 
Normal Normal Normal 
12 2 7 R - Tongue Normal Normal Normal 
Table 2. Table with clinical data of 12 patients with PRS separated into two subtypes based on cutaneous involvement. Adapted from (Sommer, 
Gambichler et al. 2006) 
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7.3 Neurologic symptoms in ECDS and PRS 
 
In a study investigating the neuroabnormalities of ECDS and PRS patients they combined the 
retrospective in-house clinical data along with the data from reviews of available literature 
(Chiu, Vora et al. 2012). In respect to the literature review 73% of patients were reported to 
have abnormalities from MRI and CT scans, whereas in the in-house review, only 19% of all 
patients had an abnormality. The main abnormalities found were lesions on T2 sequences 
that reveal inflammation and oedema. In this study, MRIs were performed on patients that 
were asymptomatic and symptomatic for any neurological problem. Abnormalities were 
found in 22% of MRI scans of symptomatic patients’ scans however abnormalities were also 
found in 17% of the asymptomatic patients. Also there are commonly bony or intracranial 
manifestations of the disease that are visible by MRI as well as scalp tissue abnormalities 
(Polcari, Moon et al. 2014).   
This study has highlighted the importance of neuroimaging in all patients with ECDS and PRS 
regardless of neurologic involvement not only to help with treatment options but also to 
predict future problems.  
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7.4 Distinction between PRS and ECDS 
 
PRS and ECDS are often thought of as overlapping disorders with some researchers of the 
thought that PRS is just a more severe and widespread form of ECDS. Conversely, some would 
argue they are completely separate disorders. 
The most distinguishing clinical feature is the cutaneous involvement in ECDS that is not 
present in PRS, but this is not always sufficient to distinguish the two. Both entities show 
atrophy and thinning at the affected site as well as sclerosis. Hyperpigmentation and alopecia 
are found more commonly on ECDS but can be present in PRS. Histological examination of 
both shows evidence of dermal fibrosis in ECDS that is rarely present in PRS. Palpation of 
lesions has also been shown useful in differential diagnosis. In some cases of ECDS there is no 
sclerotic involvement but this is most commonly found in younger patients where the lesion 
has not been evolving for long and has a violaceous hue (Orozco‐Covarrubias, Guzmán‐Meza 
et al. 2002). Histopathological features are adnexal atrophy, mononuclear cell infiltrates and 
sclerosis. PRS and ECDS has similar ANA positive results (25% and 28.4%). In addition, the level 
of CNS and ocular involvement was reported to have similar levels. 
In a global study of 205 people with PRS by Stone 2003, it was suggested that PRS and ECDS 
could be the same disorder and are very commonly found alongside one another. This online 
survey was the largest study of facial sclerosis but is based on the response of the patient 
directly. 21% of the participants reported the dual diagnosis of PRS and ECDS by their doctor. 
The study showed participants 3 pictures. Two pictures of cases of hemifacial atrophy of the 
lower face and a picture of ECDS. 31% of participants reported having both the “line” of ECDS 
and the lower face hemiatrophy suggesting a possible relationship or overlap of the diseases.  
41 
 
This study also asked participants where on the face they were affected and where else on 
the body. All had PRS of the face, 63% had it on the forehead and 51% of these participants’ 
PRS had a linear pattern on the forehead. In 10% of participants, the linear lesion touched the 
corner of the eye, in 20% the lesion extended to the mid-eyebrow and 19% of patients’ lesions 
extended to within one centimetre of the mid-line of the face. The cheek (75%), chin (43%), 
lips (55%), teeth and gums (50%) and tongue (25%) were also frequently affected. 
Interestingly, 19% of participants reported involvement of arms, legs and/or trunk alongside 
the PRS. This indicates not only a possible relationship between PRS and ECDS subtypes but 
also a connection between PRS and LLS. It must be stressed however that this study had no 
control group and there is likely some responder bias (Stone 2003).  
In a study of 54 patients with PRS and ECDS it was hypothesized that the two disorders share 
a similar pathogenesis and both should be included in the banner head of linear morphea, but 
that in fact they are distinct diseases. In this study, 53.6% of the patients who were diagnosed 
with PRS were also shown to have ECDS lesions. More studies reported the incidence of both 
diseases appearing alongside were 42% and 41.7% respectively. Conversely the patients with 
ECDS, 36.6% of them were shown to have PRS (Falanga, Medsger et al. 1986, Sommer, 
Gambichler et al. 2006).   
Many CNS related illnesses, mainly headaches and seizures have been found associated with 
ECDS and PRS in numerous studies. In (Stone 2005) 11% of PRS patients reported a diagnosis 
of epilepsy. In another study of PRS and its relationship to the CNS (Blaszczyk, Królicki et al. 
2003), 21% of PRS patients (with and without co-diagnosis of ECDS) reported seizures. 
Another study reported 13% of PRS, ECDS and both had seizures (Tollefson and Witman 
2007). Zulian found 8% of ECDS and PRS patients had seizures (Zulian, Vallongo et al. 2006). 
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Computed Topography (CT), Magnetic Resonance imaging (MRI) and EEGs have all been used 
in the search for brain abnormalities in PRS and ECDS patients. Intracranial abnormalities have 
been described in patients with seizures (Blaszczyk, Królicki et al. 2003, Zulian, Athreya et al. 
2005).  
It has been suggested in the case of both ECDS and PRS that they both follow the pattern of 
the trigeminal nerve in terms of skin presentation. As shown earlier by Resende et al. 1991 
the SNS could possibly be involved whether it is hyper- or hypodysfunction of the SNS along 
the trigeminal nerve. This would suggest they are the same spectrum of one disease affecting 
certain trigeminal nerve branches with varying severities and therefore variation in cutaneous 
involvement. This might also account for the neurological and ocular complications in both, 
the high incidence of them appearing together and the difficulty in differential diagnosis. 
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8. Misdiagnosis 
 
One of the most daunting aspects of LLS and morphea for patients is the high rate of 
misdiagnosis and the typical delay of several years before the correct diagnosis is reached. In 
a study based on children with morphea at Great Ormond Street Hospital consisting of 50 
patients, the delay to diagnosis was analysed. The average age of the patients in the study 
was 5.2 years (0.1-14.4). 86% of the patients had LLS and 8% had LLS in combination with 
circumscribed morphea. From families of the patients it was determined that the average 
delay before doctor consultation after the first symptoms were noticed was 1.2 months (0.2-
48.7). Patient families first suspected bruise, burn, atopic dermatitis, fungal infection, vitiligo, 
insect bite or other unknown causes (Weibel, Laguda et al. 2011).  
The average delay of referral by the family doctor to a specialist i.e. dermatologist, was 7.5 
months (1-70.9 months). For 64% of patients it was at this point that a correct diagnosis was 
made, the rest had no diagnosis or a misdiagnosis (a common misdiagnosis being port-wine 
stain) (Nijhawan, Bard et al. 2011). Overall it was reported that the delay to diagnosis after 
disease progression was averaging 11.1 (1.8-70) months (Weibel, Laguda et al. 2011). Others 
studies report delay in diagnosis at 18 months with 20% of patients waiting over 24 months 
(Zulian, Athreya et al. 2005).  
Common differential diagnoses of morphea is erythema chronicum migrans, granuloma 
anulare, cutaneous mastocytosis, drug reaction, lichen sclerosus and others. The 
hyperpigmentation in morphea can suggest differential diagnoses such as Café-au-lait spots, 
post-inflammatory hyperpigmentation and lichen planus actinicus. Atrophy can also be 
compatible with scarring, lichen sclerosus and acrodermatitis chronica atrophicans. 
Sclerosing skin occurs with pretibial myxedema and necrobiosis lipoidica. ECDS is often 
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confused with panniculitis, focal dermal hypoplasia, lupus erythematosus profundus, steroid 
atrophy and panniculitis (Kreuter, Krieg et al. 2009).  
 
9. Treatment 
 
There are three main treatment types recommended in morphea. Topical drugs, 
immunosuppressive systemic compounds and phototherapy. Treatment is much more 
successful when the disease is diagnosed early. However, as is evident from literature and 
clinical experience, early diagnosis can be rather difficult. Many variables must be considered 
when treating the disease. These variables fall into two main categories. First is disease 
activity. 
• Has a new lesion appeared in the last 3 months? 
• Has a pre-existing lesion increased in size? 
• Is there moderate to severe erythema or erythematous borders? 
• Has there been use of imagery to document disease activity or progression? 
• Has induration of the lesions increased? 
• Has alopecia gotten worse? 
• Is the skin biopsy showing an active disease? 
• Is there an increase in creatine kinase (CK)? 
Second is clinical damage 
• Is there atrophy of the dermis? 
• Is there atrophy in subcutaneous tissue? 
• Is there dyspigmentation of the tissue? 
• Is there increased thickness in the centre of the lesion? 
(Careta and Romiti 2015) 
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Many treatments for LS and LLS have been used with varying and often disappointing results. 
Immunosuppressors methotrexate (MTX) and cyclosporin A (CyS) are commonly used with 
the aim to dampen the overactive immune system in patients and to reduce fibrosis of the 
skin. It is a first-line treatment in up to 50% of cases of LLS. In a study of roughly 460 LLS 
patients MTX was used as treatment in 44% of patients and CyS in only 2% (Zulian, Athreya et 
al. 2005).    
A study of 34 patients with active LS lesions (Weibel, Sampaio et al. 2006) treated with a 
combination of corticosteroids (CS) e.g. prednisone and MTX showed that in 94% of patients 
the disease stopped progressing. Over time, the disease improved in all patients. Treatment 
was stopped in 47% of patients when the lesions were considered inactive. However, 44% of 
these patients relapsed, resulting in renewed treatment. Side effects were described as 
minimal and transient. At completion of the study, 71% of the patients had inactive lesions 
(Weibel, Sampaio et al. 2006, Kreuter, Krieg et al. 2009).  
According to a survey from the Childhood Arthritis and Rheumatology Alliance (CARRA) of 70 
clinical centres, focusing of pediatric rheumatology, a combination therapy of CS and MTX is 
the favoured treatment in North America. Of the 650 clinical cases that had been treated by 
doctors who participated in this study nearly all were treated with combination therapy. A 
major issue with this treatment is that no large-scale clinical trial has been performed to 
investigate the correct dosage and treatment time. Also there is no information about efficacy 
and response to treatment between different subtypes of morphea (Li, Feldman et al. 2010).  
In a 2012 study of 36 patients to determine to best dosage of MTX and CS therapy it was 
found that an initial high dose of subcutaneous treatment of MTX (1 mg/kg/week max 25 
mg/week) for two years was optimal. Subsequently the treatment method was altered to the 
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same MTX dosage but to an oral vector for 6 months followed by dose reduction over the 
next 6 months provided the disease was inactive. This was combined with oral prednisone 
daily (2 mg/kg/day tapered to 0.25 mg/kg/day). What they found was that the lesions stayed 
in remission for the entirety of the treatment in all patients (Torok and Arkachaisri 2012). 
Despite the promising results, this study was not a randomized, placebo-controlled study 
unlike the study by Zulian, et al. 2011. This double-blind study randomized 70 morphea 
patients 2:1 for oral MTX treatment versus a placebo. Treatment began with MTX (15 
mg/m2/week max 20 mg) for 12 months and a short course of CS (1 mg/kg/day) for 12 weeks. 
It was found that any adverse side effects were tolerable and lesion size decreased 
significantly though some patients (n=3) developed new lesions (Zulian, Martini et al. 2011). 
Topical, oral and intravenous steroids are also given to patients in an estimated 42% of cases 
of LLS to treat inflammation. In Zulian et al. 2005 topical steroids were used in 13% of patients 
and oral steroids in 28%. A common treatment of ECDS in the clinic is triamcinolone acetonide 
mixed with lidocaine (10-40 mg diluted 1:2 to 1:4) injected intralesionally however there has 
been no studies determining its effectiveness. Systemic corticosteroids has shown some 
success when used alone or in combination with other therapies (Zulian, Athreya et al. 2005, 
Weibel, Sampaio et al. 2006, Kreuter, Krieg et al. 2009). One study on the use of steroids in a 
monotherapeutic approach in ECDS patients for 17 months showed some improvement 
however, up to a third of these patients relapsed after therapy ended (Joly, Bamberger et al. 
1994). 
D-penicillamine, a chelator, is also used in up to 30% of patients. However, there is no proof 
that it is effective at any dose and there is a high level of side effects reported (50%). These 
side effects can be quite severe ranging from rashes, diarrhoea, nausea and leukopenia (low 
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white blood cell counts). The benefits of this treatment and it effectiveness are therefore 
debated with much scepticism about whether or not it should be prescribed (Zulian, Athreya 
et al. 2005, Kreuter, Krieg et al. 2009).  
Other, less common, therapies used are psoralen and ultraviolet A (PUVA), vitamin D 
(Calcipotriol) and NSAIDs. Low-dose PUVA phototherapy in combination with topical 
treatment of calcitriol has been shown to have successes when the disease is localized to the 
skin. There was a noticeable reduction in fibrosis and decrease in hyperpigmentation that 
maintained after follow-up appointment a year later. Mild skin irritation was reported from 
the phototherapy, however there was no other side effects (Gruss, Von Kobyletzki et al. 2001, 
Kreuter, Gambichler et al. 2001). This treatment has been found to be successful in softening 
the affected skin in ECDS in a limited number of patients (Gambichler, Kreuter et al. 2003). 
Treatment with the antifungal compound griseofulvin, colchicine and immunosuppressive 
drugs (Orozco‐Covarrubias, Guzmán‐Meza et al. 2002). Treatments do not reverse the effects 
of the disease, however it can sometimes be helpful in stopping the disease spread. 
Mycophenolate mofetil (MMF) has also been shown to be beneficial as an alternative 
treatment to MTX and CS, as some patients can be resistant or intolerant to the treatment. It 
has been shown to soften the affected skin (Marsol 2013). In a study of 10 patients, a dose of 
600-1200 mg/m2 given twice daily. All patients showed an improvement in lesion size and 
sclerosis. There is, however no in-depth analysis of its efficacy but future studies can 
determine its usefulness (Martini, Ramanan et al. 2009, Mertens, Marsman et al. 2016).  
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Treatment of LLS as suggested by Marsol above is quite different to other forms on morphea. 
In the case of generalized morphea, phototherapy is the preferred first treatment followed 
by prednisone and methotrexate and finally MMF (Figure 8). Plaque morphea is a more 
limited and superficial subtype of morphea and thus topical treatments are nearly exclusively 
recommended in these cases (Marsol 2013, Careta and Romiti 2015).  
 
Phototherapy: PUVA cream or 
bath/ UV-A1 (intermediate to 
low doses, 3-5 sessions per 
week for a total of 40 sessions), 
narrowband UV-B 
Linear localized scleroderma 
Face, limbs and joints 
Mycophenolate mofetil  
Methotrexate, 15-25 mg/week 
+ Prednisone, 0.5-1 mg/kg/day 
Figure 9. Adapted from Marsol. A proposed sequence of treatment of patients with LLS (Marsol 
2013) 
If no response 6-12 
within months 
If no response 
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Surgery is often sought as a treatment, as stable scarred lesions of sufficiently small size can 
be removed by excision. This treatment is mostly reserved for adults as it is of the utmost 
importance that the lesions are completely inactive. A period of several years stability without 
inflammatory events suggests clinical inactivity. In some cases, waiting for disease inactivity 
is not possible, for example in cases where differences have arisen in arm or leg length due 
to lesions inhibiting growth. Epiphysiodesis must be performed during childhood regardless 
of disease stage or activity. If this is the case, the patient growth must be monitored hereafter 
in combination with a systemic immunosuppressive treatment (Kreuter, Krieg et al. 2016). 
Cosmetic surgeries have been used in ECDS and PRS treatment. Autologous fat grafting, 
insertions of fillers and removal of affected skin are all surgical options but must only be 
performed in patients with inactive lesions (Figure 9) (Karaaltin, Akpinar et al. 2012).  
There is as of yet no agreed nor perfect treatment for morphea and LLS. It appears to be case 
dependent. However, the most advantageous tool is an early diagnosis. There are numerous 
treatments the most successful ones being PUVA treatment sessions or MTX with CyS 
treatment.  
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Figure 10. Surgical reconstruction in a patient with PRS A) PRS affecting the left cheek  
B) post-surgical reconstruction (Raposo-do-Amaral, Denadai et al. 2001) 
A B 
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10. Differentiation from Systemic Scleroderma (SSc) 
 
The term “scleroderma” is the hardening and thickening of organs due to deposition of 
collagen. In morphea the sclerosis is limited to skin and subcutaneous tissue sometimes with 
some extracutaneous involvement. SSc is the most severe connective tissue disorder. Once it 
presents it becomes debilitating and often fatal with the poorest prognoses for patients with 
early onset. It is a multisystem disease characterized by immune dysregulation, visceral and 
cutaneous fibrosis and vasculopathy. SSc has two categories based on pattern of skin 
involvement, limited cutaneous sclerosis and diffuse cutaneous sclerosis. 70% of patients 
have pulmonary involvement, which is the highest cause of mortality (Abraham, Krieg et al. 
2009, Elhai, Meune et al. 2011, Ramos, Silver et al. 2015). Other organs can become involved 
such as heart, gastrointestinal tract and kidneys.  
Aside from visceral organ involvement, SSc is differentiated from morphea by symptoms like 
Raynauds phenomenon, capillaroscopic abnormalities and sclerodactyly. Both diseases have 
symptoms such as malaise, myalgia and fatigue and sometimes positive autoantibody 
serologies (Fett and Werth 2011, Amaral, Marques Neto et al. 2012). No specific serological 
markers for LS are available as of yet. Interleukins 2, 4, 6 and 8, and surface molecules CD23 
and CD30 have previously been reported in some cases of LS but no substantial relationship 
has been shown  (Kreuter, Krieg et al. 2009). There are many genes that have been found to 
be associated with SSc. Most of the genes that have been implicated in SSc are immune genes 
that modulate immune reactions (Ramos, Silver et al. 2015). As of yet, no studies have 
attempted to find a genetic link between SSc, morphea and LLS.  
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Somatic Mutations and Mosaicism 
 
1. Blaschko’s lines 
 
Blaschko’s lines (BL) are the observed patterns of lesions in cutaneous mosaicism disorders. 
The patterns were first described in 1901 by German dermatologist Dr. Alfred Blaschko. He 
analysed 150 patients with epidermal and sebaceous nevi and made a composite diagram of 
the distribution on the body showing “S” shapes on the abdomen, “V” shapes on the back and 
arcs on the chest (Figure 11A) (Blaschko 1901, Molho-Pessach and Schaffer 2011). The BL 
model was then expanded upon by Dr Rudolf Happle in 2001 when he analysed and included 
the patterns on the head and neck (Figure 11B). 186 pictures of patients with lesions on the 
head and neck were compiled and again a composite diagram was made. He described “V” 
shapes on the neck, spirals on the scalp, perpendicular lines with intersection on the face and 
an hourglass pattern was found on the nasal ridge (Happle and Assim 2001, Molho-Pessach 
and Schaffer 2011).  
These dermal patterns represent the coordinated proliferation, migration and apoptosis of 
ectodermal cell during normal embryological development. The patterns are always present 
in each individual and remain invisible in healthy skin but will be apparent in diseases that 
follow these lines (Biesecker and Spinner 2013). 
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Figure 11. Blaschko’s lines on A) the body, front and back (Blaschko 1901) and B) the head 
(Happle and Assim 2001) 
A 
B 
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2. Germ layers of the embryo 
 
After fertilization a zygote forms. The zygote undergoes cell division and cleavage, making 
genetically identical cells in a hollow ball with the outside consisting of a single layer of cells. 
This is called a blastula. The blastula then undergoes gastrulation to create a multi-layered 
structure called a gastrula, which contains the germ layers (Figure 12). In humans three germ 
layers form endoderm, mesoderm and ectoderm. Christian Pander determined in the 1820s 
that from these three layers all the organs of the embryo will arise.  
Ideally, during embryogenesis all of the cells remain genetically identical but often mistakes 
in mitosis occur. Though there are some fail safes to correct mistakes in DNA duplication some 
mutations remain. If a mutation arises in one cell, all the descendants of this cell will contain 
the mutation.  At the early stages of embryogenesis there are fewer cells so the earlier the 
mutation arises the higher the number of cells that will contain the mutation. This alteration 
of the genotype results in the presence of two genotypes in one organism. This is called 
mosaicism. 
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Figure 12. Embryo at 16 days (gastrula) showing origin of three germ layers.  
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3. Mosaicism 
 
Mosaicism is named after the art of using different pieces of coloured glass and tiles to make 
patterns or images. It is the presence of two genotypes that originated from a single 
homogenous zygote (Paller 2004). It is differentiated from chimerism, which also has two 
different genotypes but arises after the fusion of two zygotes leading to two separate cell 
lines in one individual. Mosaicism is quite rare but the most widely known examples are in 
phenotypes such as heterochromia iridum (the difference in colour of eyes, skin, or hair), the 
variations in colours of dog coats and the most infamous mosaicism of all, cancer.  
Cutaneous mosaicism is also found in dermatological diseases in humans that follow 
Blaschko’s lines. Mosaicism can be germline (gonadal), somatic or a combination of the two 
called gonosomal. Germline mosaicism is when the gametes of a person carry the mutation, 
while the rest of the cells do not. This will affect the children of this individual. Somatic 
mosaicism is when the mutation is found in the some i.e. cells that are not germ cells. For this 
reason, these mutations are not inheritable and will arise spontaneously (Figure 13) 
(Biesecker and Spinner 2013).   
There are two types of cutaneous mosaicism. The most common form is type I. This is when 
the mosaic skin is linear and follows Blaschko’s lines but uninvolved, surrounding skin is 
healthy. This type of disorder was first demonstrated in patients with epidermal nevi. Keratin 
19 mutations were found in affected Blaschkoid skin, whilst there was no such mutation in 
the normal skin. Histological analysis of affected skin showed stratum corneal thickening and 
epidermolysis not present in healthy skin.  
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Type II cutaneous mosaic has been described. This is when the lesions of a disease follow 
Blaschko’s lines and its effects are severe but there is diffuse skin involvement to a lesser 
extent. Poblete-Gutiérrez et al. 2004 have described this where they studied a patient with 
Hailey-Hailey disease, an autosomal dominant disorder. On analysis of severely affected skin 
versus surrounding less affected skin, they found a mutation in the ATP2C1 gene was present 
in both. In the severely affected skin there was a loss of heterozygosity event. This means the 
heterozygous mutation was found in affected skin of the patient but where there was a 
mosaic loss of heterozygosity, the effect of the mutation was doubled (Paller 2004, Poblete-
Gutiérrez, Wiederholt et al. 2004).  
 
 
Figure 13. Types of mosaicism A) Somatic, arising spontaneously in a tissue, not heritable                          
B) Gonosomal, affecting some tissues including gametes resulting in them possibly being passed to 
offspring                                                                                                                                                                       
C) Gonadal, present in gamete or sex organs only (Biesecker and Spinner 2013) 
A B C 
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4. Mosaicism in Mendelian Disorders 
 
Mendelian disorders are the most widely known and understood pattern of inheritance. This 
is where an affected parent or both parents pass a disease-causing gene onto their children 
via any of three possible ways; autosomal dominant, autosomal recessive and X-linked. Most 
disorders are inherited in this way. The mutations that cause these diseases can more rarely 
arise de novo in a somatic pattern. Several Mendelian disorders have been described in a 
mosaic form.  
 
4.1 Apert syndrome 
 
Apert syndrome (AS) is a severe disease characterized by craniosynostosis, mid-face 
hypoplasia and syndactyly. This means the patients have fused prematurely fused cranial 
plates, an underdeveloped mid-face and fused fingers, resulting in severe disfigurement. The 
premature fusion of skull bones is also detrimental to intellectual development. A diagnosis 
is generally achieved in early life. Another feature of AS is severe acne, which generally 
develops during puberty (Henderson, Knaggs et al. 1995). Genetic analyses of patients with 
AS have unearthed various FGFR2 mutations in patients. FGFR2 (fibroblast growth factor 
receptor 2) is an important gene in numerous processes including cell growth, wound healing 
and embryonic development. Mutations in FGFR2 have been associated with many severe 
congenital cytoskeletal disorders (Kiritsi, Lorente et al. 2015).   
In one case of severe acne in a 12-year-old boy appearing on previously hypopigmented 
lesions following Blaschko’s lines. DNA was isolated from blood and affected skin. FGFR2 was 
sequenced using Sanger sequencing. A mutation of Ser252Trp of FGFR2 was found in the skin 
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but not in the blood. This mutation has been previously described in patients with AS. This 
indicates a post zygotic mutation occurred and explains the lack of skeletal involvement in 
the patient. The severe acne was treated with oral isotretinoin, a chosen treatment for the 
acne of AS. This left the patient with scarring, replacing the comedones and inflammatory 
papules (Kiritsi, Lorente et al. 2015).  
 
4.2 Darier’s Disease 
 
Darier’s Disease (DS) also known as Darier-White or keratosis follicularis is an autosomal 
dominant disease caused by mutations in ATP2A2. It is characterized by a scaly or bumpy rash 
found symmetrically throughout the body. It is caused by a malfunction of keratinization 
disrupting cell adhesion causing acanthosis. It can range from mild to severe with the milder 
forms often going undiagnosed. Symptoms generally appear during adolescence and will 
advance to complete penetrance as an adult. ATP2A2 codes for sacro-endoplasmic reticulum 
Ca2+-ATPase type 2 pump that is found in keratinocytes and muscle cells. An estimated 140 
mutations of ATP2A2 have been associated with DS. 
Mosaicism in DS has been reported several times and is called segmental DS. Both Type I and 
II mosaic manifestations of DS have been described. Few studies have investigated segmental 
DS of yet. One such study by Harboe et al. 2011 found a mutation in ATP2A2 in a male patient 
with type I segmental DS with no familial involvement (Harboe, Willems et al. 2011). In 3 other 
similar studies involving a total of 4 patients, 3 patients were found to have mutations in 
ATP2A2 (Sakuntabhai, Dhitavat et al. 2000, Wada, Shirakata et al. 2003, Huh, Fujiwara et al. 
2007). There is some debate as to whether segmental DS is the same as acantholytic 
dyskeratotic epidermal nevi (ADEN). This is due to the presence of acantholytic lesions and 
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the observed worsening of symptoms after exposure to sunlight that is present in both 
diseases. Some studies have found mutations of ATP2A2 in ADEN (Sakuntabhai, Dhitavat et 
al. 2000). However some studies maintain these should be differentiated (Wada, Shirakata et 
al. 2003, Huh, Fujiwara et al. 2007). 
 
 
5. Mosaicism in LLS 
 
In a retrospective study  of 65 paediatric patients with LLS were chosen for a study based on 
the availability of clinical photographs (Weibel and Harper 2008). Using computer aided 
analysis, common patterns of the lesions were found. 31 patients had LLS on the trunk and 
limbs and 38 had either ECDS or PRS. The investigators found that LLS follows Blaschko’s lines 
on both the body and the head. This study suggested that LLS is likely caused by a somatic 
mutation that causes a genetic mosaicism. If LLS is caused by a genetic mosaicism along BL, 
this could also explain why there are often more than one lesion and the incidence of co-
diagnosis of LLS with PRS. The mosaic cells could therefore be susceptible to LLS and then 
triggered by some factor that is still unknown (Weibel and Harper 2008, Careta and Romiti 
2015). 
Unlike most common types of mosaicism, morphea does not occur in ectodermal structures 
(section 2.3). All subtypes of morphea, including LLS, cause sclerosis of mesodermal-derived 
tissues (Paller 2004, Fett and Werth 2011). Cases like this have been described before in 
atrophoderma of Moulin or Goltz syndrome, where the affected areas follow Blaschko’s lines, 
but the disease affects the dermis (Weibel and Harper 2008). This explains why there is no 
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pattern of inheritance of LLS when family history of patients is investigated (Christen-Zaech, 
Hakim et al. 2008, Fett and Werth 2011). 
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Genetic investigation of somatic mutations 
 
1. Background 
 
Patients affected with any given disease do not usually demonstrate the exact same pattern 
of signs and symptoms. The somewhat unpredictable variability is the main difficulty for 
diagnosis of many conditions. Variability can be due to many factors that are specific to each 
individual. Such factors include the environment, modifier genes, the epigenome and the 
synergistic effect of other mutations in the patient. This results in variation in penetrance 
between patients. High penetrance indicates the disease has a strong effect on the phenotype 
and is more associated with familial Mendelian disorders, whereas low penetrance have a 
weaker disease phenotype and are associated with diseases with more complex traits 
(Voelkerding, Dames et al. 2009).  
Genomics comprises of the study of the genome of any organism to understand its structure, 
function and sequence. This focuses on the genetic code as a whole rather than focusing on 
a single gene at a time. The most important advancement in the field of genomics was the 
invention of DNA sequencing. Through large-scale analysis of DNA it is not only possible to 
diagnose diseases but it bridges that gap between genotype and phenotype. 
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2. The Human genome  
 
The human genome has roughly 3 x 109 nucleotide bases. This includes both coding and non-
coding regions. The first genome was published in 2004 by the International Human Genome 
Consortium. It cost an estimated 300 million USD but was one of the most significant scientific 
leaps forward. This also became the first reference genome. 3 years later Craig Venter and his 
colleagues published the second completed genome. Comparison of the two revealed 3.2 
million SNVs (Metzker 2010). This is more than 0.01% variation between two genomes. Since 
then, new references genomes have been published and with the advent of next generation 
sequencing technologies (NGS) they have become more comprehensive. 
The reference genome Genome Reference Consortium Human Build 37 (GRCh37) (Feb. 2009) 
from University of California Santa Cruz (UCSC) also known as hg19 was used as a reference 
for all analysis and assembly in our study 
(https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.13/). According to Ensembl 
(http://grch37.ensembl.org/Homo_sapiens/Info/Annotation#assembly) this reference 
release includes 27478 contigs (overlapping sequence reads), 9 haplotypic regions of MHC 
classification (genes inherited as a group) and the chromosome length is 3.1GB. It therefore 
currently includes 20,805 protein-coding genes, non-coding genes and known pseudogenes.  
Large-scale data collections of sequence variants such as the 1000 Genomes Project (TG) 
(http://www.internationalgenome.org/) and Exome Sequencing Project (ESP) 
(http://evs.gs.washington.edu/EVS/) have unearthed the broad spectrum of human genetic 
variation. These projects have analysed genomes and exomes from all over the world and 
determined the expanses of mutations that are commonly found and, more importantly, 
uncommonly found. The projects have also gone one-step further with subgroupings of 
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datasets in geographic specific areas such as Europeans, American, Asian and Africans. This 
allows elimination of common sequence variants in the patient according to their genetic 
heritage and to focus on the rare, or as of yet, unclassified mutations. This proves invaluable 
tool for bioinformaticians when analysing patient data for disease characterization at clinical 
level.   
 
 
3. DNA sequencing 
 
The earliest form DNA sequencing was developed at Cornell University in the early 1970’s. 
The basis of this technology involved the use of DNA polymerase and nucleotide labelling 
which are still used in modern-day sequencing technologies (França, Carrilho et al. 2002). 
Improvements to the technique resulted in faster and more comprehensive methods known 
as NGS technologies (Mardis 2008). These technologies come from Illumina, Roche 454 and 
Ion torrent amongst others and they can sequence DNA with several techniques. The most 
utilized techniques are discussed here.  
 
Whole exome sequencing (WES)  
WES focuses solely on the protein-coding region of the genome. WES has proven very useful 
at the clinical level by allowing for swift implication of mutations in diseases (Bolze, Byun et 
al. 2010, Gilissen, Arts et al. 2010). It can be useful to clinicians when dealing with symptoms 
with no apparent or obvious connection to a disease or a disease with an abnormal clinical 
presentation. WES has proved an invaluable tool for rare diseases where a more personalized 
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medicine approach must be adopted in the treatment of a patient (Dyment, Smith et al. 2015). 
WES methods are described further in the Materials and Methods section. 
 
Whole genome sequencing (WGS) 
WGS is a technique where the whole DNA sequence of an organism is determined. It is the 
most comprehensive analysis of the DNA sequence. Much like WES, it has been useful in 
identifying disease-causing mutations in several genetic disorders and is an invaluable 
method in genomics (Saunders, Miller et al. 2012). This method is similar to WES as it uses 
fragmentation and library amplification thought PCR. However, it differs in that introns and 
exons are not separated resulting in a more extensive analysis (Mardis 2008). 
 
Sanger sequencing (SS) 
SS was developed by and named for Dr. Sanger and his colleagues in 1977 (Sanger and Coulson 
1975, Sanger, Nicklen et al. 1977). This method was heavily utilized in sequencing the first 
human genome. It remains one of the most highly used form of DNA sequencing. It works by 
producing a complementary strand of DNA using DNA polymerases and deoxynucleoside 
triphosphates (dNTP) monitoring the incorporation of modified nucleoside, 
dideoxynucleoside triphosphate (ddNTP) into the growing chain (França, Carrilho et al. 2002). 
SS laid the groundwork for future sequencing techniques including WES and WGS. 
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4. Choice of DNA sequencing technique 
 
In this study, WES was the preferred technique for several reasons. For one, the exome is 
estimated to be 1% the size of the genome at roughly 30 megabases. Due to the smaller size 
of the exome, a higher average coverage can be achieved with less cost and less raw 
sequence. Due to the targeted nature of WES takes 3GB of raw sequence data to achieve 75x 
coverage whereas with WGS it takes 90GB of raw sequence data to achieve 30x coverage. 
It has been estimated that 85% of disease-causing mutations are found in the exome (Bao, 
Huang et al. 2014). Currently less than 10% of the whole genome has been characterized, 
meaning there is limited clinical gain to sequence the full genome. In addition to the lower 
cost of WES when compared to WGS, there is a lower computational resources required in 
WES analysis and thus a quicker data turn around (Majewski, Schwartzentruber et al. 2011).  
SS was not chosen for this project because in this technique one can only sequence a region 
or gene which is known to be of interest. In this study, the area of interest is unknown as LLS 
has not been studied from a genetic standpoint before. It is for this reason that SS was 
concluded to be a non-viable candidate for analysing the LLS patients.  
However, SS still has an important role as it is used as a technique to confirm mutations found 
using WES and WGS. Confirming a mutation with two forms of sequencing techniques 
strengthens the argument for the presence of the mutation.   
There is a disadvantage to the targeted sequencing process of WES. The most important step 
is the separation of the exons from the introns. This is achieved using a “targeted” approach 
where oligonucleotides (short RNA molecules) are designed that attach solely to exons. This 
approach allows the researcher to design their own targets according to the specific genes of 
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interest or genes that are known to be involved with diseases. This is especially helpful for 
those who wish to screen for cancers. However, target capture is often unequal in that there 
is inefficient capture rates across the exome leading to preferential coverage of some areas 
and low coverage in others. In addition, off-target hybridization can lead to capture of intronic 
regions and can lead to over 20% of reads to be intronic reducing efficiency (Voelkerding, 
Dames et al. 2009).  
Sequencing was performed on the Illumina HiSeq platforms. Illumina was chosen for two 
reasons. Firstly, it offers paired-end sequencing. This is a technique where reading of the DNA 
by the sequencer is performed in both directions. This is helpful in unearthing genomic 
rearrangements and repetitive sequences. Secondly, a single flow cell can produce up to 
500GB of data per run. For this reason, it is possible to analyse several samples per run with 
high coverage.   
Sequencing on the Illumina sequencer begins with attachment of the prepared library to the 
flow cell. During library preparation there is a step where adaptors for the flow cell are 
attached to the DNA. The flow cell is a glass slide with lanes coated with a lawn of 2 types of 
oligonucleotides. The DNA is hybridized by one of its adaptors to one of the surface 
oligonucleotides of the flow cell. A copy of the hybridized DNA is created by a polymerase and 
the original template is washed away. Next, bridge amplification takes place where the strand 
folds over and the adaptor binds to the second type of oligonucleotide. There is a copy made 
and this is then denatured resulting in two strands of copied DNA attached to the flow cell. 
This process is repeated and simultaneous reactions occur throughout the flow cell amplifying 
the number of copies of each DNA read. 
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Reverse strands are removed and forward strands are now sequenced. Fluorescently tagged 
nucleotides are added to the growing read. Each time a nucleotide is added the clusters are 
excited by a light source emitting a fluorescent signal. Wavelength and intensity of this signal 
is representative of the added base which is recorded by a camera. The forward strand then 
duplicated in a process similar to bridge amplification. The forward strand is removed and the 
reverse strands are now sequenced. All samples are separated according to the specific 
barcode given to each sample. This is now ready for bioinformatic analysis. 
 
 
5. Formalin fixed paraffin embedded material for WES 
 
Formalin is a favoured fixative in histopathology for examination and long-term preservation. 
It preserves the cells and their spatial relationship as well as carbohydrates and proteins 
amongst other large molecular structures. This allows detailed morphological analysis of the 
cell layers by a histopathologist, often an important step in diagnosis (Wong, Li et al. 2014). It 
is a preferred fixative because formalin penetrates the tissue easily and cross-links with tissue 
in a covalent reaction with minimal shrinkage and distortion of the tissue (Thavarajah, 
Mudimbaimannar et al. 2012). Formalin has been used in museum collection for long-term 
storage of samples for more than 150 years but this method of storage can cause DNA damage 
in many ways. Fragmentation and cytosine deamination can have negative repercussions on 
sequencing and can cause unreproducible sequencing artefacts (Figure 14) (Wong, Li et al. 
2014, Hykin, Bi et al. 2015).  
Fragmentation can be bothersome for many types of analysis, which requires largely intact 
DNA, for example, comparative genomic hybridization, however, for WES the fragment size 
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of the input DNA averages 150bp. This level of fragmentation is not often reached in FFPE 
samples. Therefore, even fragmented FFPE samples can be used successfully for WES. 
 
 
 
 
Sequencing artefacts are caused by the deamination of cytosine to uracil or methylated 
cytosine to thymine. This can result in cytosine nucleotides being reported as thymine (C→T) 
after sequencing. These errors can lead to false-positive results. One solution is to increase 
sequencing depth. It has been found that at an allelic frequency (AF) of 10-25% these C→T 
artefacts are less apparent as opposed to the disproportionate level found at AF 1-10% 
(Wong, Li et al. 2014). A more effective solution is the treatment of the FFPE DNA with uracil-
DNA glycosylase (UDG) sometimes also called UNG. UDG is a repair enzyme, which locates 
uracil in DNA and hydrolysing the N-glycosidic bond between the base and deoxyribose. The 
base excision repair system will then repair this damage by replacing the base with the original 
cytosine nucleoside (Do and Dobrovic 2012). 
Previous DNA analysis-based studies have included primarily or exclusively SF skin or FFPE 
skin. As part of this small clinical trial, skin samples received are either SF or FFPE depending 
Figure 14. Genomic ScreenTape 
performed on ScreenTape System 
(Agilent Technologies, Santa Clara, CA, 
USA). Lanes 1 and 3 are DNA from SF 
sources; lanes 2 and 4 are DNA from 
FFPE sources. Arrows show fragment 
size. FFPE ~2,500bp and SF >15,000bp. 
1            2            3             4 
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on when the patient was diagnosed and gave permission for inclusion. It was therefore 
important to make sure both preservation modes are of a high enough quality with negligible 
differences to be included in one study. SF samples can be kept in -80°C until DNA is extracted 
with some DNA degradation but no significant damage. The downstream effects of formalin 
on DNA must be avoided to prevent false positive mutations. 
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Materials and Methods 
 
Patients and clinical samples 
 
Skin samples, blood and saliva were received from patients as part of the LLS clinical trial 
(number: NCT02222038 https://clinicaltrials.gov/).  
Inclusion criteria for patients are 
• Male and female  
• Between 5 and 30 years old  
• Histologically confirmed and well phenotyped LLS by a clinician  
• ECDS with or without therapy  
• Lesion on any site of the body 
Exclusion criteria 
• Patients with signs of SSc (nailfold capillary, Raynaud phenomenon, sclerodactyly) 
• Patients with any of the other 4 subtypes  
• Patients with diagnosed gadolinium-induced scleroderma 
• Patients with post-irradiation scleroderma 
• Patients who have not given written consent 
 
19 patients were included for analysis. Clinical data was available for 17 of these patients and 
data was recorded in Microsoft Excel 2013 (Microsoft Corp., Redmond, WA, USA) (Table 8-
13). The clinicians took biopsies using local, topical anaesthetic cream (EMLA®) and a local 
injection of Lidocain 1% (1-2 mL). Patients with ECDS had an MRI to investigate the presence 
of intercranial abnormalities. If these patients were under 7 years or are experiencing anxiety, 
general anaesthetic was used and the biopsy was taken from these patients while 
anesthetized. Biopsy wounds were closed with self-dissolving or non-dissolving stiches.  
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A clinician collected 5mL EDTA blood from all patients. Local topical anaesthetic cream 
(EMLA®) was used in small or anxious patients to minimize pain and discomfort. Saliva was 
also collected from patients using Oragene DNA OG-500 (DNA Genotek Inc., Ontario, Canada) 
and both blood and saliva were sent to the laboratory at room temperature via courier.  
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Processing of biological samples  
 
Skin samples received were either formalin fixed paraffin embedded (FFPE) (10% formalin: 
3.7% formaldehyde in water and 1% methanol) or fresh punch biopsies taken by the clinician 
which were subsequently snap frozen (SF) (FFPE=9, SF=10) (Thavarajah, Mudimbaimannar et 
al. 2012). Biopsies taken after commencement of the study were between 4-5mm. They 
include dermis and epidermis of lesional skin only. Biopsies were halved with one-half to be 
FFPE embedded for histological analysis and the other half to be included in the study 
(~2mm). Fresh biopsies were placed in 1.0mL Cryotubes (Thermo Fisher Scientific, Waltham, 
MA, USA) and the whole tube was placed in liquid nitrogen to freeze them quickly and then 
stored long-term at -80°C.  
Blood and affected skin were taken from 19 histologically confirmed LLS patients and WES 
was then performed pairwise. DNA was extracted from FFPE skin samples by taking 10x10µm 
slices using a microtome HM325 (Thermo Fischer Scientific, Hampton, New Hampshire, 
United States). DNA was then extracted using the GeneRead DNA FFPE kit (Qiagen, Hilden, 
Germany) with the protocol modified accordingly for increased input of slices. The suggested 
input is one slice at 10µm but due to the very small size of embedded skin, paraffin is instead 
trimmed away from embedded skin to facilitate deparaffinization. The kit involves a 
treatment step with uracil N-glycosylase (UDG), an enzyme shown to counteract cytosine 
deamination of DNA by formalin (Do and Dobrovic 2012).  
Digestion of SF skin was performed by incubation in extraction buffer (1M Tris, 0.5M EDTA, 
Tween 20) and proteinase K (Roche, Basel, Switzerland) at 55°C overnight followed with a 10 
min heat shock at 95°C to deactivate the proteinase K (Qiagen, Hilden, Germany). This 
digestion degrades skin complex protein structure and releases skin cells into the solution 
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increasing efficiency in DNA extraction. DNA was extracted from digested skin using QIAamp 
DNA blood mini kit (Qiagen, Hilden, Germany). DNA quality was checked using both a 
NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and a 
Qubit 3.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). 
Peripheral blood mononuclear cells (PBMC) were extracted from EDTA blood using a density 
gradient. Blood was gently pipetted onto Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, 
United Kingdom) in a 50mL Falcon tube (Fisher Scientific, Hampton, NH, USA) to form two 
layers (Figure 15A). Blood was centrifuged through Ficoll to separate blood according to 
density (2,500 rpm for 20min) (Figure 15B). The PBMC layer was extracted and cells are 
washed twice with phosphate buffered saline (PBS) pH 7.4 (Gibco by Life Technologies, 
Carlsberg, CA, USA) by centrifugation of the extracted PBMC and PBS mixture (1,500rpm for 
5 min). Cells were resuspended in 200µL of PBS and DNA is then extracted from them using 
QIAamp DNA blood mini kit (Qiagen, Hilden, Germany). 
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Figure 15. Ficoll extraction A) Layers prior to centrifugation. Blood pipetted on top of ficoll 
B) after centrifugation, cells are separated out according to density in a gradient  
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Whole Exome Sequencing 
 
1. Library preparation 
 
Input material was 200ng of genomic DNA. Quality and degradation of the genomic DNA was 
measured using the Genomic DNA ScreenTape System (200bp to > 60’000bp) on a 
TapeStation 2200 (both Agilent Technologies, Santa Clara, CA, USA).  Samples were sonicated 
using a Covaris E220 to achieve a size of 150 - 200bp (Figure 16A) as per specifications in 
SureSelectXT Target Enrichment System for Illumina Paired-End Sequencing Library Protocol 
(Version C0, December 2016)(Chen, Im et al. 2015). Size was confirmed using Agilent High 
Sensitivity D1000 ScreenTape System (Agilent Technologies, Santa Clara, CA, USA). End repair, 
adenylation and adaptor ligation was performed using SureSelectXT Reagent kits (Figure 16B-
D) (Agilent Technologies, Santa Clara, CA, USA) and clean-ups between steps was performed 
using Agencourt AMPure XP magnetic beads (Beckman Coulter Inc., Brea, CA, USA).  
End repair  
The T4 DNA polymerase and Klenow enzyme are used to blunt the ends of the sonicated DNA. 
The 3’ overhangs are removed and the 5’ overhangs are filled in using the exonuclease activity 
in a 30 min incubation at 20°C. 
Adenylation 
‘A’ bases are added to the 3’ end using the Exo(-) Klenow enzyme by incubation at 37°C for 
30 min. This prepares the DNA for adaptor ligation.  
Adaptor ligation 
Single ‘T’ bases are present on the adaptors allowing them to be ligated to the DNA by DNA 
ligase for 15 minutes at 20°C. Adaptors allow the DNA to be attached to the flow cell, facilitate 
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primer attachment during PCR amplification and barcode attachment. Libraries are then 
amplified by PCR and subsequently cleaned to prepare for hybridization. 
Hybridization 
Biotinylated oligonucleotides, SureSelect Human All Exon V5/V6 (Agilent Technologies, Santa 
Clara, CA, USA), that are specific to exon regions only are hybridized to the libraries in a 24 
hour incubation at 65°C. Dynabeads MyOne Streptavidin T1 magnetic beads (ThermoFisher 
Scientific, Waltham, MA, USA) are used to separate exons from introns and other impurities. 
Streptavidin attaches to the biotin on the oligonucleotide-DNA hybrid and a magnet is used 
to separate them (Figure 16). 
 
A final PCR is performed on all libraries using the same forward primer but with distinctive 
8bp reverse primers. These act as barcodes to enable libraries to be distinguished from one 
another when pooled on the flow cell during sequencing. Molarity and quality were 
determined in all samples using the Agilent D1000 ScreenTape System (Agilent Technologies, 
Santa Clara, CA, USA) and a qPCR. The sample concentrations are then adjusted to 10nM and 
pooled together prior to be entered into the sequencer. Paired-end 125bp sequencing was 
performed on HiSeq 2500/4000 Illumina platform. 
After sequencing the data is extracted and the libraries are cleaned up and separated by the 
bioinformatics team at the Functional Genomics Centre Zurich (FGCZ) according to the 
barcodes.  
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Figure 16.  
A) Fragmentation of the genomic DNA, green is intronic regions and blue is exonic  
B) Fragmented DNA has blunt ends  
C) Blunt ends fixed by end repair   
D) Adenylation (yellow) is performed on the 3 prime end. 
E) Adaptor are ligated to the adenylated regions. The prepared library is bound to 
biotinylated oligonucleotides in a 24hr reaction.  
 
             
A B 
C D 
E 
Biotinylated 
oligonucleotides  
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F 
Streptavidin-coated magnetic 
beads.  Streptavidin binds biotin 
Figure 16.                                                                                                                                                          
F) Biotinylated oligonucleotides bound to the exons only. Streptavidin-coated magnetic beads 
added.  
G) Magnetic beads coated with streptavidin binds to biotin on oligonucleotides. Magnet is used 
to separate exons from introns  
H) Exons are amplified and ready for attachment to Illumina flow-cell                                                                             
G 
H 
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Bioinformatics Analysis 
 
2. Genome analysis toolkit (GATK) 
 
Sequencing output files were received in the FASTQ format. FASTQ files contain sequence 
data in text form with corresponding quality scores. Paired-end sequencing results in a 
forward and reverse file for each sample both averaging 2 to 4 GB each. FASTQ files were 
aligned to the reference genome (hg19) using Burrows-Wheeler Aligner (BWA-MEM) 
(SourceForge). BWA-MEM works by creating a compressed full-text substring index using 
Burrows-Wheeler transformation for compression. This can be used to detect patterns, their 
locations and the number of occurrences of these patterns in the text (SourceForge). The 
output of this is a SAM file which contains aligned sequence data in a tab delimited form (Li 
and Durbin 2010). This is then converted to a binary form called BAM file which, like a SAM 
file, lists the sequence data but is highly compressed, therefore the file size is smaller, making 
subsequent analysis steps faster. 
Quality control and analysis were performed using the GATKv3.5 guidelines from Broad 
Institute using reference genome hg19 (McKenna, Hanna et al. 2010, DePristo, Banks et al. 
2011, Auwera, Carneiro et al. 2013). Deduplication of sequencing data to remove reads in 
areas with abnormally high numbers was performed using Picard Tools v2.7.1. This is to 
ensure read statistics such as read depth are not skewed by PCR artefacts. BaseRecalibrator 
(GATK) was used to adjust base quality and detect errors in base quality. Output from the 
analysis pipeline is an altered BAM file.  
Files were individually analysed for variations from the reference genome (hg19) using 
HaplotypeCaller from Broad Institute. HaplotypeCaller works by searching for regions in the 
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sample that differ from the genome and then reassembles reads at this region allowing highly 
accurate calling of SNPs and indels even is areas with more than one variant present 
(Highnam, Wang et al. 2015). 
 
 
3. Somatic variant analysis 
 
3 somatic callers, VarScan v2.3.9 (Koboldt, Zhang et al. 2012), MuTect 2 (Cibulskis, Lawrence 
et al. 2013) and Strelka Somatic Caller (Saunders, Wong et al. 2012) were used for each sample 
pair (Blood = Germline, Skin = Somatic). All somatic callers were originally developed to 
identify somatic mutations in cancer samples allowing for high sample heterogeneity by using 
a non-cancerous in-patient control. 
 
VarScan2 
VarScan2 uses exome data and searches for somatic mutations and copy number alterations 
by using a heuristics and a Fisher’s exact test while analysing germline and somatic samples 
simultaneously (Koboldt, Zhang et al. 2012). Fisher’s exact tests analyse frequency 
distribution data to find statistical significance. This method is often used when sample sizes 
are small. Heuristics is a method of problem solving which make assumptions that are not 
considered “perfect” but uses available data and methods to find the most optimal solution 
possible.  
82 
 
Strelka 
Strelka detects small indels and SNPs while simultaneously analysing germline and somatic 
samples. It uses a Bayesian approach, which is a statistical method where the probability of 
the hypothesis is changed and updated according to new evidence or data available. The high 
level of sensitivity is achieved by considering the normal sample as germline plus some 
incidental noise and the somatic sample as germline plus some somatic variation (Saunders, 
Wong et al. 2012).  
MuTect2 
MuTect2 is similar to the previous version, MuTect, which uses a Bayesian classifier and highly 
specific filters to enable detection of somatic mutations at low allelic fractions. Unlike 
MuTect, MuTect2 uses de novo assembly of haplotypes in a region with detected variation 
(Cibulskis, Lawrence et al. 2013). 
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4. Annotation and quality control 
 
Annotation of somatic mutations is performed by Combined Annotation Dependent 
Depletion (CADD v1.3) (Wang, Li et al. 2010, Koboldt, Zhang et al. 2012, Kircher, Witten et al. 
2014). CADD reports findings from multiple databases (e.g. PolyPhen, SnpSift) showing all 
types of information on the mutations e.g. minor allele frequency (MAF), amino acid changes 
and positions and damage prediction. CADD also has a single metric which integrates and 
weighs information from other databases into one score which assess how “damaging” a 
mutation is. CADD does this by ranking the ~8.6 billion single nucleotide variations (SNV) 
according to their magnitude and then scales the Phred score from 0-40. Scores of >20 
indicate the SNV is in the top 1% of damaging mutations and SNVs with >30 are in the top 
0.01%. 
All mutations of interest were finally quality controlled manually using visualization software.  
Integrative Genomics Viewer (IGV) (Thorvaldsdóttir, Robinson et al. 2013) was used to 
compare sequencing data from the analysis pipeline to the reference genome. IGV is an 
application, which allows for interactive exploration of your data. The input file format used 
here is BAM however it can support other file types. IGV allows you to choose your reference 
genome and analyse your genome or other NGS data in this context. It uses a process called 
“data-tiling” where summarizations of the data are precomputed at several resolution scales. 
Each scale is separated into tiles along the genome that are viewable on the display. It is 
possible to upload several exomes at a time therefore the sample of interest can also be 
compared inter- and intra-patient to confirm true somatic mutations and confirm rarity. To 
do this the somatic sample is compared to the corresponding germline sample as well as 
uninvolved control exomes, to confirm a mutation of interest is absent from all controls.  
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Picard Tools‐2.7.1 (SAM to BAM)  
Picard Tools‐2.7.1. Remove Duplicates 
Removes the duplicates from PCR 
 
 
 
  
Somatic analysis Single variant analysis in individual  
BWA (FASTQ to SAM) 
Aligned to hg19 
A 
Figure 17. Bioinformatic analysis. Step by step analysis of WES data. Each sample is analysed 
together and individually. 
Pairwise entry in somatic caller 
MuTect2, Strelka and VarScan2 
Single calling of each sample 
Haplotype Caller 
Annotation of interesting mutations 
CADD, VEP and Annovar 
Annotation of interesting mutations 
CADD, VEP and Annovar 
GATK.  
Recalling and quality control 
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5. Germline analysis  
 
In order to perform an analysis of germline mutations 80 in-house samples from the 
Caucasian cluster without LLS were chosen as controls using principal component analysis. A 
multisample genotype-called VCF file for controls (n = 80) and cases (n = 19) was created using 
GenotypeGVCFs from GATK v3.6. A germline analysis was performed using Efficient and 
Parallelizable Association Container Toolbox (EPACTS) (Kang).  
EPACTS performs two types of analysis. First, it searches for a single variant that is found in 
the affected samples and controls with different allele frequencies. Second, it measures the 
burden of mutations in genes and searches for a gene that has an increase of rare variants in 
cases when compared to controls.  
EPACTS also filters samples according to their consequence: truncating, alternative and 
synonymous. Truncating mutations result in a premature stop codon, alternative mutation 
result in a change in amino acid and synonymous mutations are when the nucleotide changes 
but this still codes for the same amino acid. Mutations are further separated into dominant 
and recessive mutations. Dominant mutations are when there is a single copy of the mutation. 
A recessive mutation is when both copies of the gene carry the mutation.  
To search for a single variant, EPACTS performed a Wald test. A Wald test is a parametric 
statistical analysis which eliminates variants that are likely having no effect. For a gene-based 
approach, Fisher’s exact and SKAT-O tests were used. A SKAT-O test is a test that looks at the 
multiple-variants at the same region and looks for association with a phenotype (Wu, Lee et 
al. 2011). 
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Output data was separated according to dominant (MAF < 0.01) and recessive (MAF < 0.05) 
mutations. The MAF for recessive mutations have a higher cut off. This is because the MAF 
deals with the frequency of a mutation in the population where mutations are predominantly 
in one copy of the gene. Two copies of the mutation is much less likely however, since MAF 
does not take this into account, the stringency setting must be more lenient.  
For each output Q-Q plots and Manhattan plots were created. The QQ plots represent the 
expected p-vales of the data plotted against the actual p-values. Output Manhattan plots 
represent p-values of each data point according to chromosome.  
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6. HLA analysis of LLS patients  
 
Three HLA allotype callers were used to determine the HLA allotypes of the LLS patients and 
60 controls that do not have LLS. The callers use NGS data to infer allotypes. The HLA gene 
cluster is located on chromosome 6. HLA typing has previously been time consuming as it 
required PCR amplification with specific primers or the use of sequence-specific 
oligonucleotides during WES or NGS. Several callers have been developed to find HLA 
allotypes of patients without the need of these techniques (Szolek, Schubert et al. 2014). As 
NGS technologies such as WES and WGS are adopted frequently in clinics now, it is possible 
to use these callers on the data already available and avoid repeat experiments. The callers 
used in this project are OptiType (Szolek, Schubert et al. 2014), VBSeq (Nariai, Kojima et al. 
2015) and BWA-kit (Burrows-Wheeler-Aligner-kit 2016).  
 
OptiType 
This program uses NGS data to infer HLA allotypes using an integer linear programming 
approach. It has been shown to achieve an accuracy of 97% (Szolek, Schubert et al. 2014). 
VBSeq 
WES data is realigned along the reference genome (hg19) using BWA-MEM and reads that 
mapped along the HLA regions are extracted. Unmapped sequences are then removed and 
re-aligned along all HLA sequences from the IMGT/HLA database and then extracted. Both 
extracted files were combined and aligned with BWA-MEM. HLA alleles are estimated using 
Bayesian inference (Nariai, Kojima et al. 2015). 
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BWA-kit 
BWA-kit is a package for HLA allotyping. It has two scripts. One for downloading the human 
reference sequence and another for mapping reads to the HLA regions. It can also use 
alternative contiguous sequences which represent different haplotypes, to improve read-
mapping. 
Inconsistencies were found in MHC Class II between all 3 HLA callers in the same patient, to 
this end the analysis just focuses on MHC Class I (Major, Rigo et al. 2013).  
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7. Comparative genomic hybridization 
 
High quality DNA samples of 3 patients (i.e. samples with the lowest level of degradation) 
were chosen for Comparative Genomic Hybridization (CGH) (Beaudet 2013, Asadollahi, Oneda 
et al. 2014). The array was performed using CytoScan (2.6 million markers) (Affymetrix Inc., 
Santa Clara, CA, USA) to find chromosomal structural abnormalities such as large-scale 
deletions and duplications. The patient karyotypes were then compared to 820 in-house 
controls (Institute of Medical Genetics, Zürich) and 1038 Affymetrix controls with healthy 
karyotypes. The data set of each patient's sample was evaluated with Affymetrix® 
Chromosome Analysis Suite (ChAS). This is used to rule out commonly found or non-damaging 
chromosomal copy number abnormalities and chromosomal aberrations.  
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8. Copy number variation (CNV) analysis 
 
Copy number variation (CNV) is an event that differ between two genomes that is larger than 
1 kilobase. These changes are too small to be seen in genomic hybridization experiments as 
these are not sensitive enough to detect such small alterations. CNVs encompasses gains and 
losses of DNA. Somatic CNV events such as duplication of oncogenes and deletion of tumour 
suppressors have been described in cancer (Liu, Morrison et al. 2013, Qin, Liu et al. 2015). 
CNV events have not, as of yet, been implicated in non-cancer diseases. 
CNV analysis was performed using Sequenza v2.1.2 (Favero, Joshi et al. 2015) using WES data. 
Pileup files were generated from exome BAM files using Samtools v1.3.1 (Li, Handsaker et al. 
2009). Pileup files contain base-pair information facilitating the calling of SNPs and indels. 
Pairwise analysis of samples was performed using pileup2seqz from the Sequenza package 
(Figure 18) (Favero, Joshi et al. 2015).  
                                     
 
Figure 18. Sequenza 
analysis of CNV 
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9. Loss of heterozygosity 
Samtools-v1.3.1 (Li, Handsaker et al. 2009) was used for input file preparation for the somatic 
mutation callers. VarScan v2.3.9 (Koboldt, Zhang et al. 2012) was used to investigate possible 
loss of heterozygosity (LOH) mutations as a genetic cause in LLS. LOH is an event where a 
region of DNA is lost on one chromosome resulting in only one copy of a gene. This is 
damaging as a heterozygous mutation becomes homozygous due to the lack of a second copy 
of the gene. 
 
 
                                                                                                                                                                                                                                                                             
10. Determination of the sensitivity of somatic callers and deep sequencing 
 
A test BAM file containing chromosome 21 only was created for 5 test samples using 
PrintReads (GATK). BAMSurgeon (Ewing, Houlahan et al. 2015) was used to insert a directed 
synthetic mutation in the test BAM files. BAMSurgeon can insert mutations at a designated 
allelic fraction. Mutations were inserted at 2 regions with different read depths (DP), DP20 
and DP100. DP is how many times a single nucleotide has been sequenced. These fabricated 
mutations were inserted at allelic fractions ranging from 0.05 to 1 at 0.05 increments. These 
files were then entered into all 3 somatic callers to determine the degree of coverage 
necessary for a mutation to be called in a highly heterogeneous sample. The control samples 
were the same chromosome 21 test files without the inserted mutation. 
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Results  
 
Analysis of sequencing data  
 
1. Sample type comparison 
Quantification of differences between preservation types was performed to confirm 
conformity and legitimise inclusion of both FFPE and SF samples into one study. Skin of 3 
healthy persons was received post-routine surgery, split in half with half placed in formalin 
and half snap frozen. An analysis of the coverage and quality of FFPE samples when compared 
to SF of the same patient was performed. Sample types were analysed and compared in 
various aspects including average coverage and specificity. Average coverage for SF (DP 24.52 
± 2.6, n=3) and FFPE (DP 26.21 ± 1.7, n=3) (Table 3) are comparable with >90% of exons 
achieving over 20x coverage (Figure 19A).  Specificity of SF (57.01 ± 0.47, n=3) and FFPE (57.67 
± 1.98, n=3) (Table 3) are also comparable. Number of C to T mutations was determined in 
the FFPE samples and compared to the SF skin of the same patients. Burden of C changes in 
FFPE was found to be comparable to that of SF samples (Figure 19B). No significant changes 
were found between sample types, so we concluded both FFPE and SF could be included in 
the same study. 
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Average 
coverage 
Specificity 
SF  (n=3) 24 ± 3 57 ± 0.47 
FFPE (n=3) 26 ± 2 58 ± 2 
Figure 19. Comparison of modes of skin 
preservation.                                                        
A) Coverage of FFPE vs SF in WES data,               
B) Number of C to T mutations in 
corresponding samples  
A 
B 
Table 3. Quality of WES 
data of FFPE compared to 
SF 
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2. Somatic analysis of LLS patients 
 
After sequencing, the analysis pipeline was followed and output data underwent quality 
control analysis. The analysis showed average read depth (DP) of >80 was achieved for each 
sample. The CADD database was used to annotate the somatic variants called by the 3 variant 
programs. Somatic analysis of annotated mutations began with the search for a rare and 
predicted damaging mutation in common between patients. Mutations with a minor allele 
frequency (MAF) over 0.01 in European populations were filtered out. MAF frequencies were 
determined from data of the Thousand Genome Project (TG_MAF) and Exome Sequencing 
Project (ESP_MAF). Mutations with a CADD score below 15 were also filtered out to isolate 
mutations that were predicted to be damaging. Synonymous mutations were removed. 
Results from PolyPhen and SnpSift were consulted when scrutinising each mutation. No single 
damaging and rare SNP mutation was found to be in common between more than 5 patients 
(Strelka) (Table 4). Use of Integrative Genome Viewer (IGV) to visualise these mutations ruled 
them out as promising candidates because of presence of mutations in unaffected controls 
or presence of the mutation in germline samples. Sometimes the DP of the mutation in the 
germline is too low for detection by the program therefore it will conclude it is a somatic 
mutation. No indel was found in common between more than 2 patients (Table 4). 
 
 
 
 
 
Numbers of 
patients 
SNPs Indels 
1 60’681 3’840 
2 5’392 340 
3 118 0 
4 11 0 
5 1 0 
6... 19 0 0 
Table 4. Number of SNPs and 
indels found in common between 
patients, non-synonymous only 
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3. Gene-based somatic analysis 
 
A similar analysis was performed with the aim of finding a single gene affected with different 
somatic, rare and damaging SNP and indel mutations in common between the patients. This 
was achieved by filtering for the rare and damaging somatic mutations of all patients. Genes 
affected with these somatic mutations were then isolated. The list of affected genes of all 
patients were compiled. The number that each gene appears in the compiled list was found. 
Genes that were most frequently affected were analysed first. 
No single gene burdened with somatic mutations was found in common between the 
patients. 10 patients appeared to have HLA-DRB1 mutations, however IGV visualization 
revealed that these mutations were most likely due to aligning artefacts as HLA regions have 
high variation from the reference genome. 5 patients had a SNP in PRSS3 and CDC27 genes 
and 4 had a SNP mutation in ANKRD36 and MUC16 genes (Table 5). Both genes were ruled 
out as increased scrutiny into these somatic mutations showed these mutations were not true 
somatic mutations as some were present in the control samples in a low allelic fraction 
undetectable by the somatic mutation callers, making them appear somatic to the program. 
In addition, several mutations were in fact germline upon visualization.   
Number of 
samples 
Number of affected 
genes 
1 595 
2 35 
3 11 
4 2 
5 2 
6... 19 0 
 
Table 5. Somatically affected genes, 
rare, damaging (synonymous 
included) 
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4. Pathway-based analysis 
 
STRING online database v10.5 was used to find associations between somatically affected 
proteins in the LLS cohort with the hopes of unearthing a particular pathway with a high 
burden of mutations. All genes affected with a somatic mutation in any patient were entered 
into the program. Pathways with the highest amount of mutations were isolated and the 
mutations involved were individually analysed. Proteins in the ubiquitin mediated proteolysis 
(UMP) pathway were found to have several somatic mutations. All involved somatic 
mutations were shown to be false positives using IGV as the mutations in question were 
actually germline and/or found in control samples.  
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5. Germline analysis 
 
Gene-based germline analysis did not yield any gene burdened with mutations that were not 
present in controls.  
There was one gene, DNASE1L2, affected with a near exome-wide significant p-value (3.9-6). 
This gene was affected with 3 recessive mutations, 2 non-synonymous and 1 synonymous 
(16:2287496_T/C, 16:2287501_T/C, 16:2287491_G/C) mutations (Figure 20). DNASE1L2 is a 
paralog of DNASE1, an enzyme involved in binding of calcium ions and has deoxyribonuclease 
activity. The two, non-synonymous mutations had a MAF of 0.04 and the synonymous 
mutation had a MAF of 0.026. Use of IGV confirmed at least one of these mutations was 
present in every patient. However, more than one of these mutations was found in control 
samples (unrelated individuals) resulting in them being ruled out as risk factors for LLS.   
In single mutation analysis no p-value was found to have a higher than the expected threshold 
p-value (Figure 20C) however all mutations with a low p-value were visualized on IGV. A 
heterozygous mutation (rs74700936) was found in one gene ARNT2, aryl hydrocarbon 
receptor nuclear translocator, it is involved in the xenobiotic responsive element. This 
mutation was found in in 5 of the 19 patients. The mutation was found to be much less 
common in controls. This is a mutation in the 3’ UTR (untranslated region) in exon 19. Previous 
mutations in exon 13 of this gene have been described in Webb-Dattani syndrome, a 
neurological disorder. EPACTS predicted it as significant (p-value 0.0083616). However, it was 
ruled out as a causative mutation of LLS as annotation program CADD predicted it to have 
very low effect on protein function (CADD=1.91), SnpSift and PolyPhen could not predict an 
effect. Its MAF was quite low at 0.04 however, this is not a very rare mutation. 
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Figure 20. A) Manhattan plot of the p-values of each gene being significantly affected with 
germline mutations plotted according to chromosome. Red ring highlights the gene DNASE1L2.                                                                    
B) Is a QQ-plot of the expected p-values of genes vs the observed p-values. Red ring highlights the 
gene DNASE1L2.                                                                                                                                                
C) QQ-plot of p-values of single variants. 
C 
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Other somatic analyses  
 
6. Comparative genomic hybridization 
 
CGH analysis of 6 affected skin samples found no interesting chromosomal aberrations in 
common between patients. All aberrations in the patients were shown to be present in the 
control samples. All controls are healthy with normal karyotypes. Likewise, when patients 
were visualized individually, no significant or rare chromosomal aberrations was found. All 
aberrations were shown to be present in healthy control samples (Figure 21).  
 
 
7. Copy number variation analysis 
 
Analysis of somatic CNV events in all patients did not reveal an event in common between all 
patients. When comparing all the samples pairwise no single somatic CNV event was found in 
common between all patients. Indeed there was no event in common between any two of 
the patients. A second analysis focused on regions with different CNV events overlapping 
between patients. No region was affected with different CNV events in overlapping regions. 
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A 
B 
Figure 21. Screenshot of the ChAS program for viewing karyotypic data. Here the program shows A) a large scale deletion on chromosome 8 of a patient.       
B) Shows the same deletion and similar deletions affecting the same areas in controls. 
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8. HLA allotypes 
 
HLA Class I analysis was performed on all patients. Results of MHC Class I allotypes were 
compared between the 3 allotype calling programs. Allotypes in all 3 were consistent in all 
patients between all 3 programs. MHC Class II genes, were inconsistent between all three 
callers and the results were unreliable with little to no overlap. It is difficult to call MHC Class 
II data from WES data and this region is highly variable and leads to difficulties for the program 
when calling. Therefore we had to restrict the analysis to focus on MHC Class I only. Allotypes 
of 50 confirmed Swiss exomes to act as controls. 
First, to evaluate the HLA allotypes of our patients the allotype of blood and skin were 
compared in each patient. A somatic alteration in allotype has not been previously described 
as a cause of genetic disease. It was concluded that there was no allotypic differences in the 
affected area. Second, the burden of certain allotypes was investigated within the cohort and 
compared to our controls. As LLS is an immunological disorder, a unifying allotype possibly 
acting as a driver of the disease was theorized. There was no allotype with a particularly high 
burden in the cohort. Third, our cohort was compared to published statistics from the Swiss 
population to hopefully unearth an unusual pattern (Buhler, Nunes et al. 2012). The samples 
in our cohort reflected the available data on Swiss allotypes and the HLA allotype was ruled 
out as a possible driver of LLS (Figure 22).  
Of the HLA-A allotypes 02:01 is most common, 22% of the Swiss population has this allotype. 
This reflects our cohort where 28% have the 02:01 allotype. 14% of the Swiss population and 
13% of the cohort have 01:01. 12% of patients and 8% of Swiss controls have 03:01 (Figure 
22A, 22B). These are the 3 most common allotypes in the cohort and they roughly reflect the 
Swiss population.  
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The most common HLA-B in Switzerland is 44:02 (11%) which reflects this cohort (11%). There 
is an abnormally high subtype found in the cohort, 35:03 is found in 11% of the cohort (Figure 
22C, 22D). This does not reflect literature where it is rare ~1%. However, similar allotypes are 
more common, 35:01, 35:02 and 35:08 (6%, 2% and 1%). No more than 4 patients had this 
allotype so it doesn’t implicate this as a factor.  
The most common HLA-C allotype in Switzerland is 07:01 (12%), however in this cohort only 
5% of patients had this allotype. In the cohort 06:02 is the most common allotype (16%) but 
is less common in the Swiss population (6%). This is abnormally high because one patient had 
two copies of this allotype. 02:02 is also elevated, 13% in patients but only 7% in the Swiss 
population (Figure 22E, 22F). 
Some allotypes in HLA-B and -C are elevated or decreased when comparing the cohort to the 
Swiss population. However, none of these allotypes were present in more than 6 of the 
patients. The abnormally high burden of these allotypes occurs because in some patients the 
allotype was present on both alleles causing the percentage affected to look abnormally high 
but not widespread in the cohort.  
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Figure 22. Distribution of allotypes A) HLA-A of cohort, B)HLA-A of 60 in-lab Swiss controls, C) HLA-B of cohort, D) HLA-B of Swiss controls E) HLA-C of 
cohort and F) HLA-C of Swiss controls 
110 
 
9. Related phenotypes 
 
Skin presentation in SSc, and morphea including the LLS subtype is often similar, therefore a 
possible genetic relationship between the 2 diseases was investigated here (Ramos, Silver et 
al. 2015). SSc is not considered genetic in all patients, however several studies have identified 
some genetic factors involved such as certain genes and HLA allotypes. A list of 54 genes 
known to be involved in SSc was compiled from literature and then an analysis of how many 
of these genes were somatically affected in our patients was performed. KCNA5, a gene 
associated with pulmonary arterial hypertension in SSc patients, has been somatically 
affected with different mutations in 3 of 19 patients. These mutations were then found in 
blood in a lower allelic fraction of the patients indicating they are not truly somatic mutations.  
 
 
 
10. Loss of heterozygosity 
 
Output of LOH was analysed for a unifying event from all patient samples. Furthermore, an 
event of varying length, which was affecting the same area, was searched for. No LOH event 
was found to be present in more than one patient. LOH was ruled out of having possible 
involvement with LLS. 
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11. Somatic callers and deep sequencing  
 
The analysis of the truncated bam files with inserted mutations (DP 20 and DP 100) showed 
VarScan to be a more restrictive calling program with the most lenient of filtering settings 
(VarScan Low Table 6) resulting in mutations at an allelic fraction below 15% to be filtered out 
at both DP. MuTect2 was found to be very sensitive as it is able to detect somatic mutations 
at an allelic fraction of 5% at both DP. Strelka was shown to be more sensitive at DP 100 where 
it could find somatic mutations at an allelic fraction between 5-10% as opposed to DP 20 
where the lowest allelic fraction was 20% (Table 6).  
 
 
 
Genotype caller Allelic fraction 
 
0.05 0.1 0.15 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
VarScan (High) - - - - - + + + + + + + 
VarScan (Mid) - - + + + + + + + + + + 
VarScan (Low) - - + + + + + + + + + + 
Strelka (DP 20) - - - + + + + + + + + + 
Strelka (DP 100) - + + + + + + + + + + + 
Strelka (DP 100, 
Q5) 
+ + + + + + + + + + + + 
MuTect (DP 20) + + + + + + + + + + + + 
MuTect (DP 100) + + + + + + + + + + + + 
Table 6. Allelic fraction at which a mutation can be called as somatic by a calling program. VarScan 
investigated with DP20 sample with stringency setting Low to high. Strelka and MuTect investigated 
with both DP. 
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Following this, 4 patients were chosen for deep sequencing of both the blood and 
corresponding skin. Of these 4 patients, 2 had the skin biopsy taken from the en coup de sabre 
affected skin of the forehead. The other 2 patients had biopsies taken from the frontoparietal-
temporal lesions. Deep sequencing samples were prepared for sequencing as before. 
Maximum sequencing depth was ensured by combining the raw data with the raw data from 
the previously sequenced samples of the same patients. A sequencing depth of 352.55 (± 
26.8) for blood samples and 368.4 (± 67.7) for skin samples was achieved. Specificity of 
85.15% in skin and 83.65% in blood was achieved. Somatic analysis and subsequent 
annotation of mutations were performed as above. Number of mutations called increased by 
13.5% with the increased sensitivity (Table 7).  
Despite the increased number of mutations, no rare and somatic SNP mutation was found in 
more than one patient and similarly no somatic indel was found in more than one patient. A 
gene based analysis was also performed to find genes affected in each patient with various 
rare and damaging mutations and indels. No gene was somatically affected in more than one 
patient with both a SNP and indel. One gene, GOLGA6LA, was affected with an indel in one 
sample and a SNP in another two samples, however further scrutiny into these mutations 
ruled them out as true somatic mutations and thus as a candidate gene. 
Number of mutations called 
Normal Deep sequencing  
116‘757 134‘773 
Table 7. Number of mutations 
(SNPs and indels) called by 
haplotype caller in normal and 
deep sequenced samples 
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Discussion  
 
Patient data  
Our clinical cohort consisted of 19 patients. 2 patients had no clinical data available aside from 
confirmation of LLS diagnosis and gender. Our study included 13 females and 6 males, the 
ratio was 2.2 to 1 (Table 8). This reflects the expected gender ratio that ranges from 2-6 to 1 
in literature. Of the 17 patients, 2 patients had joint involvement. Both patients had lesions 
on the right limbs, one on the lower leg and the other on the upper arm. One patient had 
ocular involvement. This patient had ECDS on the right side affecting the face and extending 
into the scalp. Two other patients with ECDS had involvement of the CNS. Both these patients 
had lesions on the face and one had the lesion extending into the scalp (Table 12). This gives 
a total of 5 patients in the cohort with extracutaneous involvement. Studies such as Christen-
Zaech 2008 show over 50% of LLS patients have some form of extracutaneous involvement in 
the CNS, musculoskeletal or gastrointestinal.  
Unilateral lesions presented on the left in 6 patients and the right of 11 patients (Table 10). 
In literature there has been no evidence that one axis is more affected than the other. There 
were no cases of bilateral involvement in our cohort. This is to be expected, as it is quite rare. 
In a studies by (Zulian, Athreya et al. 2005, Christen-Zaech, Hakim et al. 2008), it was 
estimated that 11% of LLS patients have bilateral involvement. In these same studies ~50% of 
LLS patients had ECDS with the remaining having them on trunk and limbs. In our cohort, 6 
patients had lesions on the trunk or limbs and 11 patients presented with ECDS. The largest 
proportion of patients had 2 lesions (n=8) though 5 lesions were found in 2 patients and 8 
lesions were found in 1 (Table 10, 11). 
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Of the 17 patients, 7 did not receive systemic treatment. 10 received systemic treatment, 9 
were treated with MTX and one with another, unspecified treatment. In the cohort, only 3 
patients received topical medicine. The treatment received was a protopic ointment. All 
patients treated with protopic ointment also received MTX treatment. LLS treatment often 
requires aggressive systemic treatment and topical solutions. The 7 patients who did not 
receive systemic treatment had no other treatments (Table 13). Of these 7 patients, 3 had 
ECDS and the rest has trunk/limb lesions.  
Average age of onset in the clinical cohort was 8.1 years (Table 9). This is slightly higher than 
the consensus of literature of 6 years. The delay in diagnosis was 1.4 years, which is reflective 
of a study by Weibel et al. 2011 which found the delay in diagnosis averages 1.5 years and can 
last up to 2 years before correctly diagnosed (Table 9) (Weibel, Laguda et al. 2011). Average 
LoSSI score of the patients included in this study was 5.4 with a range of 2 to 10 (Table 8). Few 
studies include data scoring disease severity or damage in each patient (LoSCAT, LoSSI, LoSDI, 
PGA-A/D) so a comparison of our patients to those in other cohorts is not possible.   
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Exonic analysis of patients 
Specificity of capture from WES of both SF and FFPE as well as coverage was comparable in 
both sample types. In previous studies, FFPE samples are shown to have up to ~10-fold higher 
cytosine (C) to thymine (T) and this leads to sequencing artefacts. Sample treatment with UDG 
prior to DNA extraction has been shown to reverse deamination-related sequencing errors 
significantly (Do and Dobrovic 2012, Chen, Mosier et al. 2014). Inclusion of these two sample 
types to be the somatic tissue of patients was therefore approved.  
It was shown in this study that the two sample types did not lead to any problems in sample 
handling, sequencing and subsequent analysis. The conclusion is that future studies should 
include the two sample types together after processing as described above. This will be highly 
beneficial as it can increase sample size and thus the power of analysis. One limitation is that 
the analysis was performed on samples that were in formalin for a maximum of 6 months. 
The effects of formalin over a longer period of time have not yet been shown. 
Opposing the hypothesis put forward at the commencement of this study that LLS is caused 
by a somatic mutation following Blaschko’s lines, no somatic mutation, neither SNP nor indel 
was found in common between the patients. This result is surprising. The rarity of the disease 
would be compatible with being caused by a shared single mutation. The adherence to 
Blaschko’s lines would also suggest it is driven by a somatic mutation, which we did not find. 
Furthermore a gene-based analysis also showed there was no single gene affected with a 
somatic mutation in common between the patients. The presence of various mutations in a 
common gene could also have accounted for the rarity and skin pattern however this was not 
the case. It was then hypothesized that the cause of LLS was not a single gene, but a pathway 
was disrupted in each patient. Each affected gene could be different but they share a common 
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pathway. This pathway-based analysis did not reveal any pathway to be disrupted in each 
patient that could be driving LLS. 
Due to the lack of inheritance and adherence to Blaschko’s lines it is not likely that the driving 
cause of LLS is a germline mutation. This being said, it was important to investigate this as a 
possible cause to perform a well-rounded study. However, this analysis was also important as 
it could have unearthed a possible genotype that increases susceptibility to LLS.  There could 
be several factors, immunologic or metabolic, that could lead to a patient being more 
susceptible to LLS.  
The analysis of the germline did not reveal any mutations that are not present in the controls 
that held up to statistical scrutiny and IGV visualization. All mutations with an observed p-
value below but in close proximity to the expected p-value, were investigated. All mutations 
were found to be in controls in a very low allelic fraction. This shows that they are false 
positives that possibly arose from discrepancy in DP between cases and controls. 
Furthermore, in the gene-based analysis no gene was found to be affected with mutations 
that were not also present in controls. This indicates that no germline mutations in the exonic 
regions are driving LLS. 
A karyotype refers to the size, shape and number of chromosomes in an individual. Altered 
karyotypic states have been implicated in many genetic diseases such as trisomies and 
persistent polyclonal B-cell lymphocytosis (PPBL) (Mossafa and Flandrin 2002). It was a 
possibility that LLS could be caused by a rare karyotypic event occurring in a mosaic pattern. 
A subgroup of the patients were chosen for CGH analysis. CGH is a tool used to identify 
duplications and deletions on a very large scale. All patients were shown to have healthy 
karyotypes indicating neither a mosaic or germline change in karyotype causes LLS.  
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Copy number variation results from sections of the genome being repeated and it varies from 
person to person due to duplications and deletions. It is a type of structural variation. It has 
been shown in literature to be inherited but somatic changes in CNV has been implicated in 
the development of several forms of cancer. Several copy number events were found in each 
patient but no gene or area was affected in all the patients or no event was in common in 2 
or more patients. CNV events are not driving LLS in either a germline or somatic pattern 
(Favero, Joshi et al. 2015) (Thapar and Cooper 2013). 
HLA is a gene complex that codes for the major histocompatibility complex (MHC) proteins. It 
is separated into three class types, MHC I, II and III. Class I and II control the immune system. 
Class III is involved in the complement system. They are arranged on cell surfaces and interact 
with immune cells. The MHC region on chromosome 6, is a highly polymorphic region 
resulting in many different alleles called allotypes. Different classes control interactions with 
different aspects of the immune system. MHC class I code for HLA-A, B, and C. MHC class II 
code for the most polymorphic regions HLA-DP, DM, DR, and DQ. 
As part of this study, we wanted to investigate if LLS patients have a unifying allotype or a 
change in allotype between affected skin and germline. Our patients had no allotypic changes 
in skin that were not in blood. Furthermore no allotype appears to be associated with LLS as 
all the patients had various allotypes that is consistent with the distributions of allotypes in 
Switzerland (Buhler, Nunes et al. 2012). Allotypes that are known to be associated with SSc 
were investigated and no allotype was found in common (Ramos, Silver et al. 2015). A genetic 
comparison of SSc to LLS was also performed.  
WES is a technique that has proved highly valuable in studies of SSc. Though it is still unknown 
what is the cause of SSc it has helped identify risk factors for SSc development e.g. 64 variants 
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were found in a phospholipid transporter gene, ATP8B4 (Gao, Emond et al. 2016). In this study 
it was hypothesized that a connection could be made in the genetics between these two 
diseases because of the similar skin involvement and sclerosis that is indicative of both. No 
gene that has been implicated in SSc was found to be burdened with mutations in LLS. If there 
is a factor that connects these two diseases it does not lie in the exonic regions.  
Sensitivity of the 3 somatic callers was analysed due to concerns of the small biopsy size (2-4 
mm) as per guidelines of the study. This small size leads to difficulty separating skin layers (i.e. 
fibroblasts and keratinocytes). Blaschko’s lines has been shown to be caused by the epidermal 
patterns of migration of cells (Moss, Larkins et al. 1993, Weibel and Harper 2008). After the 
biopsy is taken, a large portion is taken for histological confirmation, a crucial part of correct 
diagnosis. Left for DNA extraction was 1-2mm of skin. Separating layers of such a small sample 
was difficult and isolation of keratinocytes for cell culture was unsuccessful.  Fibroblasts could 
be isolated and cultured, however fibroblasts are dermal cells. Deep sequencing has proven 
a useful method in diagnosis of neurological disorders through patient blood. In this study 
patients had a somatic mutation in the brain. Deep sequencing is used to increase the number 
of reads with the mutation and mutation detection programs were then able to pick up the 
mutation (Jamuar, Lam et al. 2014) 
In this study, input DNA for WES has an unknown ratio of keratinocyte DNA to fibroblast DNA 
and other epidermal and dermal cells. Therefore, sensitivity of the somatic callers was 
determined to find the lowest allelic fraction at which a heterozygous mutation in a 
heterogeneous sample can be found. MuTect was especially sensitive when using both types 
of data. The sensitivity of the Strelka program benefited from using deep sequencing data 
because the sensitivity of detection increased from 20% at DP 20 to 5% at DP 100. A result of 
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5% at DP 100 means the programs can call mutations at a 5% allelic fraction. This means a cell 
type, representing 10% of the sample can have a heterozygous mutation that can be found 
by the callers. Samples that had been deep sequenced also had many more mutations called 
(>13%) when compared to sequencing data with normal coverage. This can therefore be used 
to compensate for sample heterogeneity.   
After deep sequencing, several rare and damaging somatic SNPs were found in common 
between 2 of the 4 patients. Visualization using IGV showed that these mutations were 
present in the germline sample but at a lower DP possibly causing the level of false positivity. 
Some mutations were also shown to be present in uninvolved control samples.  
Taken together, no somatic or germline SNP or indel is driving LLS and no gene is affected in 
all patients. Furthermore, no karyotypic event, copy number change or HLA allotype has been 
shown to be involved in the disease in any capacity.  
Transcriptomic analysis performed by a collaborator on 4 patients did not reveal any protein 
to have increased or decreased expression in LLS skin when compared to blood. This analysis 
is indicative that the disease-causing factor is not at the mRNA level. However, this study is of 
very few patients so this experiment should be repeated by future studies.  
Possible future studies should focus on changes in epigenetics. As yet there are no examples 
of diseases following BL that are caused by epigenetic factors. However, epigenetics is quite 
a new field, the importance of which has just started to be unearthed. Future studies should 
also focus on the intronic regions. Whole genome sequencing allows for the analysis of exonic 
and intronic data. The introns are estimated to only have 15% of disease-causing mutations 
but these areas have numerous repeats and are quite large resulting in a very difficult analysis 
(Bao, Huang et al. 2014). However, within the intronic regions lie regulatory sites, binding 
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sites and splice sites amongst other. The role of the intron is often forgotten as most 
mutations are found in exonic regions but mutations here can cause several downstream  
maleffects. 
The choice to study LLS as opposed to other forms of morphea lies in the fact that it is the 
only subtype that follows BL. As other diseases following BL have been shown to be caused 
by somatic mosaicism the initial hypothesis of this study was that LLS would also exhibit this 
genetic architecture. Studying somatic mosaicism is preferable to simple germline analysis. 
Performing a germline analysis on a rare disease is difficult as one needs a large cohort and a 
large number of controls so the data holds up to statistical scrutiny. The benefit of a somatic 
analysis is the internal controls. Patients are not only compared to uninvolved exomes or 
genomes but there is further comparison of the affected tissue of the patient to the 
unaffected. The use of internal and external controls makes mosaic diseases preferable to 
study.  
Pertaining to the field of morphea and LLS research, this study is very important. Though no 
genetic factor has been pinpointed as the cause of LLS, several causative factors have been 
ruled out. The study focused solely on LLS, however it is a subtype of morphea. LLS is linked 
to the other types of morphea in many ways often making them difficult to distinguish. A 
genetic analysis of one subtype is therefore informative about morphea as a whole. This work 
is the first genetic analysis of a subtype of morphea, so it will hopefully benefit and provide 
guidance to future researchers.
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Code DOB Gender FFPE SF LoSSI Score Clinical data available 
[01002] 04.12.2005 m 
 
X 7 1 
[01003] 22.07.2003 f 
 
X 4 1 
[01004] 15.06.2001 f 
 
X NA 1 
[01005] 23.11.2005 f X 
 
10 1 
[01006] 06.11.2000 m X 
 
3 1 
[01008] 02.06.2008 m X 
 
2 1 
[04010] 29.01.1974 m 
 
X NA 0 
[02011] 04.06.1998 m X 
 
NA 1 
[03012] 19.08.1989 f 
 
X 8 1 
[01013] 13.07.2003 f X 
 
2 1 
[01014] 21.10.2008 f X 
 
3 1 
[01015] 07.03.1989 f X 
 
NA 1 
[02017] 27.09.2004 f 
 
X 8 1 
[04018] 15.07.2002 f X 
 
6 1 
[01019] 04.06.2004 f 
 
X 4 1 
[01020] 16.07.1997 f X 
 
NA 0 
[02021] 30.10.1987 f 
 
X 8 1 
[01023] 11.09.2003 f 
 
X 5 1 
[01024] 01.01.2012 m 
 
X 5 1 
Table 8. Clinical data of LLS study cohort. 1 = yes, 0 = no 
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Code Age at 
inclusion 
(months) 
Age at 
inclusion 
(years) 
Date of 1st 
manifestation 
Age at 1st 
manifestation 
(months) 
Age at 1st 
manifestation 
(years) 
Date of 1st 
diagnosis 
Diagnostic 
delay (months) 
Diagnostic 
delay (years) 
[01002] 106 8.71 01.06.2011 66.83 5.49 15.03.2013 21.77 1.79 
[01003] 134.87 11.08 01.01.2009 66.33 5.45 03.12.2013 59.9 4.92 
[01004] 161.37 13.26 01.01.2004 31 2.55 01.01.2005 12.2 1 
[01005] 109.5 9 01.07.2013 92.57 7.61 03.02.2014 7.23 0.59 
[01006] 170.4 14.01 01.06.2007 79.93 6.57 01.06.2007 0 0 
[01008] 78.5 6.45 01.06.2010 24.3 2 20.05.2011 11.77 0.97 
[04010] n/a n/a n/a n/a n/a n/a n/a n/a 
[02011] 199.97 16.44 01.01.2000 19.2 1.58 01.01.2000 0 0 
[03012] 307.13 25.24 01.01.2002 150.6 12.38 01.01.2006 48.7 4 
[01013] 138 11.34 01.01.2008 54.43 4.47 01.01.2010 24.37 2 
[01014] 74.07 6.09 01.04.2011 29.73 2.44 03.02.2012 10.27 0.84 
[01015] 315.07 25.9 01.08.2014 309.27 25.42 05.12.2014 4.2 0.35 
[02017] 126 10.36 01.01.2008 39.7 3.26 01.01.2012 48.7 4 
[04018] 154.1 12.67 01.03.2014 141.57 11.64 05.11.2014 8.3 0.68 
[01019] 133.23 10.95 01.09.2014 124.7 10.25 23.04.2015 7.8 0.64 
[01020] n/a n/a n/a n/a n/a n/a n/a n/a 
[02021] 338.7 27.84 01.01.2011 282.13 23.19 01.01.2011 0 0 
[01023] 151.63 12.46 01.12.2014 136.63 11.23 01.12.2015 12.17 1 
[01024] 52.13 4.28 01.01.2015 36.53 3 08.04.2016 15.43 1.27  
mean= 161.8 mean = 13.3 
 
mean = 99.1 mean = 8.1 
 
mean = 17.2 mean = 1.4  
median = 138 median = 11 
 
median = 67 median = 5 
 
median = 12 median = 1 
Table 9. Clinical data pertaining to manifestation and delay in diagnosis of LLS study cohort 
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Code Type of 
morphea 
Right/left Body region 1 Body region 2 
[01002] 1 1 1 
 
[01003] 1 2 1 
 
[01004] 0 1 3 
 
[01005] 0 1 2 3 
[01006] 1 1 1 
 
[01008] 1 2 1 
 
[04010] 
    
[02011] 1 1 1 
 
[03012] 0 1 2 3 
[01013] 1 2 1 
 
[01014] 1 2 1 
 
[01015] 0 1 3 
 
[02017] 1 1 1 
 
[04018] 0 1 3 
 
[01019] 1 1 1 
 
[01020] 
    
[02021] 0 2 2 3 
[01023] 1 1 1 
 
[01024] 1 2 1 
 
Table 10. Affected axis of patients in LLS study cohort. Type of morphea: 0 = linear limb/trunk, 1 = ECDS. Right/left: 1 = right, 2 
= left. Body region: 1 = head, 2 = trunk, 3 = extremities. 
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Code Location 1 Location 2 Location 3 Location 4 Location 5 Location 6 Location 7 Location 8 Number of 
lesions 
[01002] 1 2 
      
2 
[01003] 1 2 
      
2 
[01004] 7 8 9 
     
3 
[01005] 3 5 7 8 9 10 11 12 8 
[01006] 1 2 
      
2 
[01008] 2 
       
1 
[04010] 
         
[02011] 1 2 
      
2 
[03012] 3 7 8 9 10 
   
5 
[01013] 2 
       
1 
[01014] 2 
       
1 
[01015] 11 
       
1 
[02017] 1 2 
      
2 
[04018] 10 11 
      
2 
[01019] 1 2 
      
2 
[01020] 
         
[02021] 4 5 7 8 9 
   
5 
[01023] 1 2 
      
2 
[01024] 2 
       
1 
 
 
 
Table 11. Location and number of lesions of LLS study cohort. 1 = scalp, 2 = face, 3 = chest, 4 = abdomen, 5 = upper back, 6 = 
lower back, 7 = upper arm, 8 = forearm, 9 = hand, 10 = thigh, 11 = lower leg, 12 = foot 
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Code Extracutaneous manifestations  
 Joints Eyes CNS Other autoimmune disease 
[01002] 0 1 0 0 
[01003] 0 0 1 0 
[01004] 1 0 0 0 
[01005] 0 0 0 1 
[01006] 0 0 0 0 
[01008] 0 0 1 0 
[04010] 
    
[02011] 0 0 0 0 
[03012] 0 0 0 0 
[01013] 0 0 0 0 
[01014] 0 0 0 0 
[01015] 1 0 0 0 
[02017] 0 0 0 1 
[04018] 0 0 0 0 
[01019] 0 0 0 0 
[01020] 
    
[02021] 0 0 0 0 
[01023] 0 0 0 0 
[01024] 0 0 0 0 
 
 
 
Table 12. Extracutaneous manifestations of LLS study cohort. 1 = yes and 0 = no 
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Code Current treatment details  
Tx at inclusion Systemic medication Topical medication 
[01002] 3 1 2 
[01003] 1 1 0 
[01004] 1 3 0 
[01005] 3 1 2 
[01006] 0 0 0 
[01008] 0 0 0 
[04010] 
   
[02011] 1 1 0 
[03012] 0 0 0 
[01013] 0 0 0 
[01014] 3 1 2 
[01015] 0 0 0 
[02017] 1 1 0 
[04018] 1 1 0 
[01019] 0 0 0 
[01020] 
   
[02021] 1 1 0 
[01023] 0 0 0 
[01024] 1 1 0 
 
Table 13. Available data on treatment of LLS study cohort. Treatment at inclusion: 0 = no, 1 = systemic, 2 = topical, 3 = systemic and topical. 
Systemic medications: 0 = no systemic medication, 1 = MTX, 2 = MTX + systemic steroids, 3 = other. Topical medications: 0 = no topical med., 1 
= topical steroids, 2 = protopic ointment 
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Chapter 2 
 
 
Generalized Comedones, Acne, and 
Hidradenitis Suppurativa in a Patient 
with a FGFR2 Missense mutation 
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Abstract  
 
Mutations in the fibroblast growth factor-receptor gene 2 (FGFR2) have been implicated in 
numerous diseases, including nevus comedonicus (NC) and naevoid acne that have somatic 
missense mutations in FGFR2 in the affected tissue. A patient presented in our department 
with unusual, innumerable and large comedones throughout his back reminiscent of NC, as 
well as multifocal hidradenitis suppurativa and acne. Topical and systemic treatments were 
unsuccessful. Whole exome sequencing of blood-derived DNA detected a germline mutation 
in FGFR2 that was predicted to be damaging. This could explain the multifocal and severe 
nature of the disease. We suggest screening other, phenotypically similar patients, for FGFR2 
mutations. Our findings, once confirmed independently, could indicate that therapeutic 
modulation of FGFR signalling in the acne tetrad could be effective. 
 
CD Cluster of differentiation 
CADD Combined Annotation Dependent Depletion 
HS Hidradenitis suppurativa  
IGV Integrative genome viewer 
MAF Minor allele frequency 
NC Nevus comedonicus 
NCS Nevus comedonicus syndrome 
PUVA Psoralen and ultraviolet A 
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Introduction 
 
Hidradenitis suppurativa (HS) is an inflammatory skin disease that affects roughly 1% of 
Europeans. It is characterized by painful abscesses, boils, cysts, and malodorous, pus-filled 
lesions in intertriginous regions (Pink, Simpson et al. 2012, Pink, Simpson et al. 2013). It can 
follow autosomal dominant inheritance in some families, and mutations have been reported 
(Wang, Yang et al. 2010) in the gamma-secretase genes Presenilin-1 (PSEN1), Presenilin 
Enhancer-2 (PSENEN), and Nicastrin (NCSTN) in a minority (<7%) of cases. The remaining 
cohort are presumed to be sporadic or driven by other, as yet unidentified mutations.  
Nevus comedonicus (NC) is a rare (prevalence 1:45,000–1:100,000) epidermal nevus 
comprising of a group of dilated hair follicle openings filled with plugs of brownish-black 
oxidized keratin (Kofmann 1895). It is usually localized on the head and neck and was initially 
described as “localized acne” (Munro and Wilkie 1998). If it occurs as a part of the nevus 
comedonicus syndrome (NCS) (Engber 1978), it can be generalized and form linear streaks. 
HS-like lesions have been observed in NCS (Qian, Liu et al. 2015). In some cases of NC, a 
somatic mutation in fibroblast growth factor-receptor gene 2 (FGFR2) has been identified, 
namely the Ser252Trp missense mutation (Munro and Wilkie 1998). FGFR2 is expressed in 
keratinocytes, hair follicles, and sebaceous glands and has been implicated to induce 
hypercornification and comedogenesis (Melnik 2009). Germline FGFR2 mutations are also 
associated with acne, as seen in dominant Apert syndrome (Campanati, Marconi et al. 2002) 
(also comprising craniosynostosis, epiphyseal closure, and syndactyly) (Moloney, Slaney et al. 
1996, Downs, Condon et al. 1999). When occurring as a mosaic, the acne lesions follow 
Blaschko’s lines (Kiritsi, Lorente et al. 2015), the pattern of embryological cell development 
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and proliferation. In a recent case, a postzygotic mosaicism was found in exon 4 of FGFR2 
(c.758C>G, p.Pro253Arg) in low copy number. A similar mosaicism was also found in two other 
patients in p.Ser252Trp of exon 4 (Melnik 2009). 
A 49-year-old male construction worker presented with a 29-year history of multiple 
abscesses in his buttock, inguinal, and axillary regions (Figure 23) and a history of severe post-
pubertal acne conglobate. His back was studded with innumerable large comedones not 
unlike those seen in NC, however rather more spread out (Figure 23A), and with significant 
scarring. His condition had proved resistant to treatment with topical and systemic 
antibiotics, dapsone, retinoids, including acitretin and isotretinoin, zinc supplements and 
PUVA. Treatment with infliximab did have an effect on the inflammatory components; 
however, it was minimal and ultimately unsuccessful. Surgical interventions included excision 
of the left axilla and shoulder region and a transposition flap and excision of a pilonidal sinus. 
The patient is an orphan. It is known that several other people in his family including his father 
and brother had suffered from the same condition with different intensities; however, there 
is no contact between the patient and family. Requests to collect samples from family 
members were denied by the patient. Suspecting a potential genetic origin (Fitzsimmons, 
Guilbert et al. 1985), we therefore performed whole exome sequencing on blood-derived 
DNA.  
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Figure 23. Widespread abscesses present in 49-year-old male patient.                                                               
A) Back of patient showing grouped comedones and hidradenitis suppurativa (HS) scars.                                    
B) Inguinal scars.                                                                                                                                                                   
C) Close-up of open HS lesions. 
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Materials and Methods 
 
DNA was extracted from blood peripheral blood mononuclear cells as previously described in 
the “Processing of biological samples” section of materials and methods. Whole exome 
sequencing was performed as described in previous section “Whole exome sequencing” and 
bioinformatic analysis and quality control were performed as per directions in the 
“Bioinformatics analysis” subsections Genome analysis toolkit section and annotation and 
quality control of materials and methods. Bioinformatic analysis was performed with the aim 
of analysing the patient as an individual or “Single variant” analysis (Figure 17).   
All rare (MAF < 0.01) and damaging mutations (CADD >15) were extracted for analysis. First 
genes that are known to be associated with acne were analysed for mutations. All variants in 
these genes were not damaging or rare. All rare and damaging mutations were visualized, 
quality controlled and compared to controls without acne using IGV. All mutations deemed 
truly rare were entered into the Online Mendelian Inheritance in Man (OMIM) database. 
Furthermore, a literary search was performed.    
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Results 
 
A search for rare, deleterious mutations revealed that there was no such mutation present in 
any of the known HS-associated genes. However, a rare missense mutation in the FGFR2 gene 
was found in exon 5 (c.G492C, p.K164N, see table 14). This mutation is predicted (McLaren, 
Pritchard et al. 2010) to have pathological consequence on the protein by several prediction 
algorithms, namely SIFT (“deleterious,” lowest score 0), PolyPhen (“probably damaging,” 
highest score 1), LoFtool (“probably damaging,” 0.00179), Condel (“deleterious,” 1.00), CADD 
(17.05), and SNPs&Go (73% probability). MutPred resulted in 63% probability for “damaging,” 
and predicted (Li, Krishnan et al. 2009) molecular features of the mutation are loss of 
methylation at K164 (P = 0.0069), loss of ubiquitination at K164 (P = 0.0081), loss of solvent 
accessibility (P = 0.0371), and loss of MoRF binding (not significant, P = 0.0575) as well as gain 
of sheet (not significant, P = 0.1451). 
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Discussion 
 
In a patient with clinical features reminiscent of NCS, we found a new, rare heterozygous 
missense mutation in FGFR2, the gene for the keratinocyte growth factor (KGF) receptor. 
FGFR2, also known as CD332, was cloned in 1990 (Houssaint, Blanquet et al. 1990) and soon 
found to be the receptor for KGF. It has an extracellular part constructed of three 
immunoglobulin domains, a lipophilic transmembrane part, and a tyrosine kinase that 
extends in the cytoplasm. Fibroblast growth factors (FGF) can bind the extracellular domain 
and thus activate the tyrosine kinase. This leads to cell division and differentiation. The 
isoform found in ectodermal tissues such as the skin is the FGFR2IIIb, also known as the KGF 
receptor. It binds FGF-7 and 10, also known as KGF 1 and 2, as well as FGF-1, -3, -22. 
Keratinocyte growth factors are potent mitogens for many epithelial cell types but lack 
detectable activity on fibroblasts or endothelial cells. 
Germline mutations in FGFR2 underlie various craniosynostosis syndromes (Table 15), and 
somatic mutations in the same gene have been reported in NC (Munro and Wilkie 1998) and 
nevoid acne (Campanati, Marconi et al. 2002). We report a germline mutation in FGFR2 that 
may contribute to explaining a generalized, rather than mosaic, NC-like, acneiform phenotype 
with additional features of HS. As documented above, the disease proved highly treatment 
resistant, which is a common feature in NC. FGFR inhibitors, which may directly address the 
genetically driven pathogenesis, exist but have not been reported in this context. 
 
 
135 
 
Table 14. Fibroblast growth factor-receptor gene 2 (FGFR2) mutation identified in the patient. 
 
Table 15. Diseases caused by FGFR2 mutation
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